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CHAPTER 1 
 
INTRODUCTION 
 
The Cell Cycle and Mitosis 
Cell division is a fundamental process that is required for life. It is a beautiful orchestration 
of biochemical events that gives cellular life the ability to pass on its genetic material, allowing 
organisms to grow and reproduce. Cell division relies on the cell cycle machinery, an incredibly 
complex network of proteins that prepares and primes the cell to duplicate and segregate its 
genome. Cell division is arguably one of the most important events that takes place in our body, 
as the cell has to handle the genome with both care and efficiency.  As such, several diseases arise 
due to faulty cell division, such as cancer.  
 The cell cycle has four distinct phases, each depending on the success of the previous to be 
initiated. The first phase is called G1, a period of cell growth and microenvironment monitoring 
to determine if conditions are suitable for cell division. This is followed by a DNA synthesis phase, 
where the cell duplicates the genome in preparation to divide. DNA duplication is followed by 
another, shorter growth phase (G2) where the cell continues to synthesis proteins required for cell 
division. The cell cycle culminates in mitosis, whose major events include release of DNA from 
the nucleus and the creation of the mitotic spindle (Alberts et al. 2008).  
 Despite mitosis being the shortest phase in the cell cycle, lasting roughly 30 minutes, it is 
the most critical step. Mitosis itself consists of different stages, beginning with prophase and 
prometaphase, where the chromosomes condense, the nuclear envelope breaks down, and the 
mitotic spindle is built. This is followed by metaphase, where the duplicated chromosomes align 
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at the equator of the mitotic spindle. Once chromosome alignment is achieved, the cell physically 
separates the sister chromatids during anaphase, pulling them to opposite ends of the cell 
concurrent with cytokinetic ring constriction at the cell equator (Asbury 2017; Green et al. 2012). 
Within the two new daughter cells, the chromosomes decondense and the nuclear envelope reforms 
during telophase (Alberts et al. 2008).  Mitosis concludes with cytokinesis, the cleavage and 
physical separation of the two new daughter cells (Green et al. 2012). 
 The cell spends an enormous amount of energy and resources preparing to divide, ramping 
up protein production to support the duplication of organelles and the genome. To prevent waste 
and protect the integrity of division, the cell has evolved numerous safeguards to guarantee a 
successful cell cycle. These checkpoints consist of biochemical switches that induce an all-or-none 
response signaling cascade (Nurse 2000).  Cells use binary responses to control the cell cycle 
because it is equally dangerous to prematurely initiate cell cycle signaling pathways as it is to halt 
them half way through. Major check points monitor the success of DNA replication, the attachment 
status of chromosomes to the spindle, as well as microenvironment conditions (Barnum and 
O’Connell 2014).   
The Mitotic Spindle  
 The term mitosis was coined by Walter Fleming in 1882 from the Greek mitos which means 
“thread” and the Latin osis, which means “act” or “process”. Though many exciting events 
comprise mitosis, many who study it are captivated by a macromolecular machine called the 
mitotic spindle. The spindle is an impressive structure, whose fleeting existence in mitosis makes 
it even more of a mystery. The “living spindle” was first visualized in 1937 and later the structure 
was confirmed by Inoue in 1953 using polarized light microscopy (Inoué 1953).  The fibers that 
comprise the mitotic spindle are called microtubules (MT). MTs are a complex cytoskeletal 
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polymer whose main role in interphase is to provide cytoplasmic organization through organelle 
positioning and vesicle cargo trafficking (Alberts et al. 2008).  In addition, interphase MTs are 
crucial for cell motility. At the leading edge of the cell, polymerizing MTs activate Rac1 to 
stimulate actin polymerization within the lamellipodia and at the rear of the cell, MTs target focal 
adhesions to stimulate their disassembly (Kaverina, Krylyshkina, and Small 1999; Kaverina, 
Rottner, and Small 1998; Waterman-Storer et al. 1999).  In mitosis, MTs assume a new 
responsibility, creating anchor points between the chromosomes and the spindle pole.  
 
Tubulin and Dynamic Instability  
MTs are composed of αβ-tubulin heterodimers that self-assemble in a head-to-tail fashion 
to create a protofilament (Borisy and Taylor 1967).  Lateral non covalent interactions between 
tubulin protofilaments leads to the creation of a hollow, cylindrical tube that is the MT (Alberts et 
al. 2008).  The β subunit of the tubulin dimer contains an exchangeable nucleotide binding pocket 
that can bind and hydrolyze GTP. During MT assembly, GTP-tubulin adds on to the growing end 
of the polymer and creates a protective GTP-tubulin cap and subsequent GTP hydrolysis leads to 
a predominantly GDP-tubulin lattice (Carlier et al. 1984; Mitchison and Kirschner 1984).  GTP-
hydrolysis within the structure leads to a ‘bending’ of the tubulin dimer and compaction of the MT 
lattice. This compaction generates strain within the lattice and acts as a storage of energy that is 
released during depolymerization (Alushin et al. 2014).  MTs exhibit a unique feature called 
dynamic instability that allows individual polymers to switch between periods of growth and 
shrinkage within a steady state population (Mitchison and Kirschner 1984). MTs also have an 
intrinsic polarity due to the nature of tubulin protofilament assembly. The α subunit of the 
incoming tubulin dimer interacts with the exposed β subunit in the protofilament, creating a polar 
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structure with exposed α and β subunits at either end. These ends are classified as the minus and 
plus end of the MT, respectively.  The structural polarity of the polymer results in functional 
differences between the two ends of the filament, with the plus end generally being more dynamic 
then the minus end (Walker et al. 1988).  This inherent property of MTs, along with dynamic 
instability, results in the creation of dynamic networks within the cell that have the dual ability to 
explore cellular space as well as create stable structures when needed.  Furthermore, this 
dynamicity of MTs imparts the ability to drastically rearrange their cellular network at the onset 
of mitosis, disassembling the interphase MT array in a matter of minutes. Not surprisingly, the 
dynamic property of MTs is essential during mitosis. Efficiency and adaptability of the MTs within 
the spindle is crucial for spindle formation as well correcting erroneous chromosome connections.  
 
Spindle MT Structure   
 Tens of thousands of MTs make up the mitotic spindle and sub populations of MTs take 
on distinct functions.  The spindle is a bipolar structure with microtubule organizing centers 
(MTOCs), or centrosomes, at opposite ends. In general, the minus ends of the MTs are focused 
and embedded in the centrosomes, with the dynamic plus ends free to explore cytosolic space 
(Doxsey 2001).  The majority of the spindle MTs grow towards the center of the structure and fall 
into three categories: interpolar, bridging, and kinetochore MTs.  Kinetochore MTs (K-MTs) are 
bundles of parallel MTs that form a mechanical link to the chromosome via the protein complex 
called the kinetochore (Hinshaw and Harrison 2018). These bundles are the most stable MT 
population in the spindle, with a lifetime in the order of minutes (Zhai et al. 1995).  Bridging MTs, 
also known as bridging fibers, are bundles of anti-parallel MTs that connect sister K-MTs. During 
metaphase, bridging fibers help balance the interkinetochore tension and during anaphase, produce 
5 
 
sliding forces to separate the sister chromatids (Kajtez et al. 2016; Vukušić et al. 2017).  Interpolar 
MTs grow from opposite centrosomes and overlap in the cell middle, creating an anti-parallel array 
(Mastronarde et al. 1993).  This population of MTs comprises the majority of the MT density 
within the spindle and is more dynamic then their K-MT counterpart, with a half-life of less than 
one minute (Zhai et al. 1995). Despite their rapid turnover, interpolar MTs provide structural 
integrity for the spindle. Last but not least, there are astral MTs, a population of non-bundled MTs 
that grow towards the cell cortex rather than the cell middle. Astral MTs interact with actin and 
the molecular motor dynein at the cell cortex and are required for proper spindle orientation (Laan 
et al. 2012).  
 
Figure 1.1 Schematic of MT populations within the mitotic spindle. Kinetochore, bridging, and 
interpolar MTs are all located within the spindle mass. Astral MTs grow away from the spindle center and 
interact with the cell cortex.  
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Forces Within the Spindle  
 Upon observing mitosis in a living cell, it becomes clear that it is a force driven process. 
One might notice the constant motion of the chromosomes, the subtleties in spindle positioning, 
or the polymerization and depolymerization of the MTs.  These movements, in part, can be 
attributed to another intrinsic property of MTs: their ability to produce forces within cells.  MTs 
can produce both pushing and pulling forces during their polymerization and depolymerization, 
respectively. Tubulin dimers add to the growing plus end of the MT during polymerization, which 
is able produce force against boundaries in vitro (Dogertom and Yurke 1997). This force 
generation model, referred to as the Brownian ratchet mechanism, attributes thermal fluctuations 
to the occasional insertion of new subunits at the growing end, even in the presence of an external 
resisting force (Mogilner and Oster 1999; Peskin, Odell, and Oster 1993).  In cells, plus end 
polymerization in the spindle midzone uses this property to drive chromosomes further apart in 
late anaphase (Scholey et al. 2016).  Depolymerization of MTs occurs when the stabilizing GTP-
tubulin cap is lost, resulting in rapid release of the bent GDP-lattice. Cells harness the forces 
generated from MT depolymerization to pull on sister chromatids during metaphase and 
importantly anaphase, when chromatids must reach the new daughter cell (Asbury 2017; 
Khodjakov and Rieder 1996; Lombillo et al. 1995).  
 While the MTs that compose the mitotic spindle can inherently produce forces on their 
own, the mechanical processes observed in mitosis would not be possible without the orchestration 
of molecular motors. Molecular motors are broadly classified as enzymes that harness the energy 
from ATP hydrolysis to generate force inside the cell. The precise coordination and balance of 
forces generated by these motors is crucial for the success of the spindle.  
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Dynein 
 In 1965, the first MT based motor to be discovered for its role in cilia bending was dynein, 
named after the Greek word dyne, meaning force (Gibbons and Rowe 1965).  Dynein is a AAA+ 
ATPase motor that walks towards the minus end of the MT and requires the activator dynactin to 
bind to cargo and walk processively inside the cell (Gill et al. 1991).  During interphase, dynein is 
the sole retrograde transport motor, bringing endocytic vesicles towards the cell center either for 
recycling or degradation (Alberts et al. 2008).  Dynein localizes to specific areas within the cell 
during mitosis, including the spindle and nuclear membrane, where its force generation properties 
help shape the mitotic spindle. At prophase, dynein is recruited to the nuclear envelope (NE) to 
facilitate NE breakdown as well as provide forces to separate the duplicated centrosomes 
(Raaijmakers et al. 2012).  Dynein is also localized to the centrosomes. Here, dynein’s ability to 
cross-link MTs and walk towards the minus end is used to support spindle pole focusing and 
clustering (Heald et al. 1996; Tanenbaum et al. 2013).  In doing so, dynein activity at the poles 
generates inward directed forces that counteracts the outward forces that dominant during 
centrosome separation. When dynein activity is perturbed during mitosis, either via interfering 
antibodies or small molecule inhibitors, spindles are disorganized and display unfocused poles 
(Firestone et al. 2012; Gaglio et al. 1997).  Dynein is also crucial for spindle positioning as hinted 
above, where cortical dynein pulls on astral MTs on either end of the spindle (Laan et al. 2012).  
 
Kinesins 
 A second MT based motor named kinesin was discovered 20 years after dynein. Ron Vale 
and colleagues used the giant squid axon to study the mechanism of fast axonal transport and 
isolated the ATP dependent motor that powered this process (Vale et al.1985).  Kinesins are a large 
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superfamily of molecular motors, consisting of 15 family members and 45 different kinesins in 
mammals. In general, kinesins are composed of 3 major tertiary structures, simply named the 
“head”, “stalk”, and “tail” domains. The globular “head” domain houses the ATPase and MT 
binding regions of the motor and is followed by a coiled-coil “stalk” domain that is important for 
dimerization. Kinesins diverge most in their “tail” region, which generally specifies the kinesins 
function or localization (Hirokawa and Tanaka 2015).  Similar to dynein, kinesins use the 
mechanochemical coupling of ATP hydrolysis to generate forces within the cell. The kinesin 
ATPase cycle is tightly coupled to MT binding, with the motor domain cycling between low and 
high MT affinity states (Cross and McAinsh 2014).  When no nucleotide is bound to the active 
site, kinesins exist in an ‘apo’ or rigor state and interact strongly with the MT. ATP binding and 
hydrolysis weaken the motors affinity for the MT, allowing the kinesin to unbind and interact with 
a new site on the MT lattice. After phosphate release, ADP in the active site shifts the motor into 
a weak MT binding state, with the motor returning to the ‘apo’ state upon removal of ADP from 
the active site and re-binding to the MT lattice (Cross and McAinsh 2014).  The majority of 
kinesins are plus end directed motors, with the exception of Kinesin-14s and Kinesins-13s.  HSET 
is a member of the minus-end directed Kinesin-14 family that localizes to the centrosomes during 
mitosis while MCAK is a kinesin-13 family member that depolymerizes MTs (Desai et al. 1999; 
Walczak et al. 1997).  In interphase, kinesins are vital for anterograde transport of vesicles as well 
as organelle positioning. For example, when MTs are depolymerized, the Golgi complex 
undergoes fragmentation and lysosomes freely diffuse (Ba et al. 2018; Thyberg and Moskalewski 
1985). The force generation ability of kinesins is also harnessed in mitosis and will be discussed 
below.    
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Spindle Assembly: Nucleation of MTs  
 Spindle assembly begins when the interphase MT network disassembles at the onset of 
mitosis. This breakdown provides the soluble tubulin that is required to create the mitotic spindle 
de novo. Quick and efficient MT nucleation is key to building the spindle under the time constraints 
of cell division. As such, the nucleation capacity of the centrosomes increases substantially during 
mitosis, presumably through the recruitment of γ-tubulin and the γ-tubulin ring complex (γ-
TURC). γ-tubulin is a member of the tubulin family found in all eukaryotes and is highly enriched 
at MTOCs (Oakley et al. 1990; Oakley and Oakley 1989). The γ-TURC is a ring structure 
composed of γ-tubulin and other proteins that act as a template to build a MT and together with γ-
tubulin, is required for MT nucleation (Zheng et al. 1995).  The MT catastrophe frequency also 
increases substantially during mitosis (Verde et al. 1992). Changing this parameter of dynamic 
instability allows the MTs within the spindle to quickly explore the cell volume at the onset of 
mitosis. This exploration is central to the “search and capture” model, where upon nuclear 
envelope break down (NEB), the dynamic MTs emanating from the centrosomes can search and 
engage the sister chromatids (Holy and Leibler 1994). 
 Centrosomes were long believed to be the only microtubule organizing center (MTOC) in 
cells. In retrospect, it would be unwise to not have back up methods to create a structure as 
important as the spindle.  As such, it is now understood that spindle assembly is extremely robust 
and cells employ several mechanisms to protect the spindle. The most obvious clue that cells 
harness other pathways to create a mitotic spindle comes from observing female oocyte meiosis. 
Ooctyes lack centrosomes and instead depend on an acentrosomal spindle assembly pathway to 
create a bipolar spindle (Bennabi et al 2016). The acentrosomal pathway relies on MT nucleation 
originating from chromosomes. Several spindle assembly factors (SAFs) are sequestered in the 
10 
 
nucleus by α/β importins and their release depends on the small GTPase Ran and its guanine 
nucleotide exchange factor RCC1 (Kalab and Heald 2008).  RCC1 is highly enriched on the 
chromatids, resulting in a high concentration of Ran-GTP and subsequent release of SAFs near the 
chromosomes (Kalab et al 2002).  For example, the protein TPX2 is an importin cargo and its 
release promotes MT nucleation and downstream signaling pathways that promote spindle 
assembly (Gruss and Vernos 2004).  In addition, the acentrosomal pathway depends on MT motors 
to sort and organize MTs into a bipolar structure (Heald et al. 1996). Though the acentrosomal 
spindle assembly pathway is generally masked in centrosome containing cells, ablation of the 
centrosome does not interfere with formation of a bipolar spindle, signifying that back up 
mechanisms can be employed and dominate when needed (Khodjakov et al. 2000).  
 MT nucleation also occurs inside the spindle.  This process is mediated by a protein called 
augmin, which binds to MTs within the spindle and recruits the γ-TURC (Goshima et al. 2008).  
The interaction between a spindle MT and augmin promotes branching of MTs off of one another, 
adding MT density to the spindle. This population of nucleated MTs is crucial for spindle function. 
When augmin nucleation is removed from HeLa cells, spindle MT density decreases and mitotic 
progression is impaired (Uehara et al. 2009).  
 
Spindle Assembly: Centrosome Separation 
 The iconic bipolar geometry of the spindle may be its most important feature. While other 
characteristics of the spindle are indeed crucial for mitosis, any cell attempting to divide with a 
structure other than a bipole will fail.  Bipolarity is achieved only when the minus ends of the 
spindle MTs are focused at the two centrosomes.  The consequences of bipolarity failure can be 
seen in both monopolar and multipolar cells. Monopolar spindles are rosette structures whose 
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centrosomes are enclosed by a radial array of MTs and DNA due to centrosome separation failure. 
Syntelic chromosome attachments dominate and without equal tension on both sister kinetochore, 
the spindle assembly checkpoint (SAC) is activated, leading to apoptosis (Kapoor et al. 2000; Tao 
et al. 2005). Conversely, cells that form multipolar spindles are in danger of producing aneuploid 
progeny with uneven chromosome distribution (Kwon et al. 2008). Aneuploid cells are highly 
unstable and display chromosome instability, a hall mark of cancer (Ganem et al. 2007; Salmela 
and Kallio 2013).  Both monopolar and multipolar mitoses are equally disastrous for the cell and 
as such, several pathways have evolved to add robustness to the bipolar spindle to promote its 
correct formation.  
 
Figure 1.2 Schematic of spindle assembly and centrosome separation by Eg5. During interphase, the 
MT network spans the cell and acts as a ‘highway’ for cargo carrying molecular motors. When the cell cycle 
is initiated, the centrosomes duplicate and an increase in MT nucleation and MT dynamics leads to the 
formation the mitotic spindle. Eg5 is able to bind to the anti-parallel MT overlap formed between the two 
centrosomes and provides the pushing forces required for separation (inset).  
  
12 
 
After centrosome duplication, sister centrosomes remain in proximity of each other on the 
nuclear envelope and must separate before NEB. The main outward force generator involved in 
centrosome separation is the mitotic kinesin-5 family member Eg5 (Blangy et al. 1995; Sawin et 
al. 1992). Eg5 is a tetrametric kinesin that has two motor domains on opposite ends of the molecule, 
allowing Eg5 to engage two MTs at once (Le Guellec et al. 1991).  As a plus end directed motor, 
Eg5 acts as a MT slider when its motor heads are bound to anti-parallel MTs or a MT crosslinker 
when bound to parallel bundles (Kapitein et al. 2005). Eg5 localizes to the NE during prophase, 
where it can bind and slide MTs within the nascent antiparallel overlap being formed by the sister 
centrosomes (Figure 1.2, Sawin and Mitchison 1995).  Recent work suggests that Eg5 also acts as 
a MT polymerase that dwells at the MT plus end, promoting MT growth and preventing 
catastrophe, essentially generating its own track (Chen and Hancock 2015).  This novel finding 
aligns with the function of Eg5 during mitosis, allowing the motor to dwell on antiparallel overlaps 
to facilitate outward pushing forces while also creating longer MT tracks. During prometaphase 
and metaphase, Eg5 remains bound to the spindle and is enriched near the poles (Sawin and 
Mitchison 1995; Sturgill and Ohi 2013). At first, this seems like an odd localization for an anti-
parallel MT slider. One explanation comes from the observation that bipolar spindles do not 
collapse if an Eg5 inhibitor is added after bipolarity is achieved, suggesting that Eg5 is not required 
for spindle bipolarity maintenance. Moreover, Eg5 has been shown to be functional on parallel 
MTs and may play a role in pole maintenance (Groen et al. 2008; Kapitein et al. 2005).  
 Several specific and potent kinesin-5 inhibitors (K5I) have been developed over the past 
20 years and have been utilized by clinicians and basic researchers alike (Kozielski 2012). 
Researchers have taken advantage of these small molecules to study auxiliary spindle assembly 
pathways in somatic cells that do not rely on Eg5 activity for centrosome separation. To date, four 
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different groups have generated K5I resistant cell (KIRC) lines and all of them share one unifying 
feature: they require the mitotic kinesin Kif15 for viability (Dumas et al. 2018; Ma et al. 2014; 
Raaijmakers et al. 2012; Saeki et al. 2018; Sturgill et al. 2016; Sturgill and Ohi 2013).  Before this 
universal requirement for Kif15 in K5I resistance had been revealed, the kinesin-12 family 
member Kif15 was first likened to Eg5 due to its ability to rescue spindle bipolarity when 
overexpressed in K5I treated cells and later for its anti-parallel MT sliding capabilities (Reinemann 
et al. 2017; Tanenbaum et al. 2009). Kif15 was first discovered in Xenopus as a plus end directed 
kinesin, containing an N-terminal motor domain followed by a coiled-coil stalk (Boleti et al. 1996). 
Within its coiled-coil stalk lies a non-motor MT binding site that allows Kif15 to engage with two 
MTs (Sturgill et al. 2014).  In C. elegans, Eg5 is not required for bipolar spindle formation and 
instead relies on Kif15 in both oocyte meiosis and mitosis (Bishop, Han, and Schumacher 2005; 
Segbert et al. 2003; Wignall and Villeneuve 2009).  
 In human tissue culture cells, Kif15 is essential for spindle bipolarity maintenance, rather 
than generation of centrosome separation forces (Tanenbaum et al. 2009; Vanneste et al. 2009).  
Kif15 localizes to K-MTs, acting as a K-MT stabilizer and length regulator while also antagonizing 
the outward forces generated by Eg5 (Sturgill and Ohi 2013). However it is Kif15, rather than Eg5, 
that assumes a dominant role in spindle bipolarity maintenance. HeLa metaphase spindles maintain 
spindle bipolarity when treated with an Eg5 inhibitor, but collapse to monopoles if Kif15 is 
knocked down (Sturgill and Ohi 2013; Tanenbaum et al. 2009).  Cells treated with a K5I can adapt 
to loss of Eg5 activity by over expressing Kif15 (Sturgill and Ohi 2013; Tanenbaum et al. 2009). 
When over expressed, Kif15 redistributes to non-K-MTs, where it is able to compensate for loss 
of Eg5 by sliding anti-parallel MTs apart to separate the centrosomes (Sturgill and Ohi 2013). 
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 Despite being an antiparallel MT slider, centrosome separation via Kif15 is temporally and 
mechanically distinct then the Eg5 driven pathway. In HeLa cell derived KIRCs, centrosomes fail 
to separate by NEB and form a monopolar intermediate. On the path to bipolarity, monopolar 
spindles break radial symmetry to create a radial fan-shaped monoester, which then undergoes 
“reverse jackknifing”, where one spindle pole rotates 180°. Even though this alternative spindle 
assembly pathway accomplishes the end goal of bipolarity, it is not efficient, as evidenced by 
nearly 50% of cells undergoing apoptosis (Sturgill and Ohi 2013).  
 
Regulation of Mitotic Kinesins  
 Kinesin motors are vital mechanical movers in the cell that have crucial functions in both 
interphase and mitosis. Since kinesins consume ATP, a central energy source for the cell, their 
activity must be controlled to prevent fruitless ATP hydrolysis. In addition, controlling when and 
where kinesins become active allows the cell to effectively harness their power when needed, 
preventing the disaster of kinesin hyperactivity.  Kinesin activity is kept in check several ways. 
Though both interphase and mitotic motors are subjected to the same regulatory mechanisms, 
mitotic motors will be discussed as examples for each.  
 Globally, mitotic motors are regulated through control of protein levels during the cell 
cycle and cyclin dependent phosphorylation, similar to non-kinesin mitotic proteins (Verhey and 
Hammond 2009).  Beyond this, a common regulatory mechanism exploited by several kinesins is 
autoinhibition. Autoinhibition is a cis regulatory mechanism, with the C-terminal tail of the kinesin 
interacting with the motor domain. This folded conformation effectively shuts down ATPase and 
MT binding activity of the motor. Autoinhibition is a particularity effective method since the 
inhibitory component is attached to the motor itself, allowing for quick and precise inhibition. 
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Though this mechanism is most studied in the transport motor kinesin-1, mitotic motors also use 
autoinhibition to regulate their activity within the spindle (Hackney and Stock 2000; Kaan et al. 
2011). For example, the chromosome congression kinesin CENP-E is directly regulated in this 
manner, with phosphorylation by Cdk1 relieving inhibition and allowing the motor to bind MTs 
at the onset of mitosis (Espeut et al. 2008).  Similarly, Kif15 is directly regulated by its C-terminal 
tail. What makes Kif15 autoinhibition unique is that Kif15 harbors a second non-motor MT 
binding site within its coiled-coil tail, which imparts a preference for MT bundles over single 
filaments (Sturgill et al. 2014).  Together, self-regulation and a preference for bundled MTs in an 
active conformation ensures that the motor is restricted to K-MTs during mitosis. Kif15 is cytosolic 
during interphase, but does not bind to MTs, suggesting that its autoinhibition is relieved upon 
mitotic entry. Indeed, Kif15 phosphorylation by Aurora A kinase promotes its localization to the 
spindle during mitosis (van Heesbeen et al. 2017). Furthermore, Kif15 has a potential Cdk1 
phosphorylation site, but direct phosphorylation by Cdk1 has not been confirmed (Boleti et al. 
1996).  
 Interactions in trans between kinesins and their binding partners, or “receptors”, can recruit 
kinesins to their proper spindle location.  A classic example of a “receptor” that targets several 
kinesins is the midzone associated protein PRC1. PRC1 interacts with the N-terminal region of 
Kif4a, a chromokinesin that regulates midzone MT length (Kurasawa et al. 2004; Subramanian et 
al. 2013). During anaphase, PRC1 also targets the transport kinesin MKLP-1 and MKLP-2 to the 
spindle midzone, both of which are required for successful cytokinesis (Neef et al. 2006).  Kinesins 
that regulate MT dynamics during mitosis are often recruited to the plus end of the MT through 
interactions with MT end binding protein EB1 (Mimori-Kiyosue et al. 2000).  For example, the 
MT depolymerase MCAK binds to EB1 and becomes enhanced at MT tips (Lee et al. 2008).  
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 Post translational modifications can also control kinesin activity in cells. Phosphorylation 
is the most studied modification and can regulate kinesin activity in several ways.  The majority 
of phosphorylation events occur in the regulatory non-motor regions of the kinesin, thus either 
interfering or promoting an activity or localization (Welburn 2013). For example, MCAK 
phosphorylation by Aurora B kinase dampens its MT depolymerization activity during mitosis, 
presumably through interfering with its ability to bind MTs. When MCAK phosphorylation by 
Aurora B is blocked, MCAK activity is unchecked and monopolar spindles dominant (Ohi et al. 
2004). On the other hand, phosphorylation of Eg5 by Cdk1 promotes its localization to the spindle 
and is also required for spindle bipolarity  (Blangy et al. 1995; Sawin and Mitchison 1995). 
Phosphorylation can also relieve autoinhibitory interactions, such as described above for CENP-E 
(Espeut et al. 2008).  
 Finally, mitotic kinesins can be sequestered in the nucleus to prevent their activity during 
interphase.  For example, Kinesin-14 family member HSET and MKLP-1 are sequestered to the 
nucleus via their interactions with nuclear importins, ensuring that they are only released when 
needed after NEB (Goshima and Vale 2005; Liu and Erikson 2007).  
 
Targeting Mitosis for Chemotherapies  
 Plants that contain active MT targeting compounds, such as the extract from the toxic 
blooming flower autumn crocus, have been used to treat human conditions since the Ancient 
Egyptians (Florian and Mitchison 2016).  It would be many millenia later when the compound 
from that flower would be isolated by scientists and named Colchicine. Colchicine binds to curved 
tubulin dimers and forces them to remain curved, leaving them unable to polymerize (Barbier et 
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al. 2010). Though not used a chemotherapy, Colchicine’s ability to arrest mitosis ignited the field 
with curiosity about cell division in different tissues and organisms (Florian and Mitchison 2016).  
 
MT Targeting Compounds  
 Many of the first chemotherapeutics discovered in the United States target microtubules 
and are still routinely used to treat certain cancers. The first class of MT targeting compounds was 
the vinca alkaloids, discovered in the 1950s from natural products (Noble, Beer, and Cutts 1958).  
Vinca alkaloids such as vinblastine bind to the tubulin dimer and have been used primarily to treat 
lymphomas and germ cell malignancies. The sequestration of tubulin dimers by vinca alkaloids 
eliminates the pool of polymerization competent tubulin, effectively shutting down MT dynamics 
(Florian and Mitchison 2016).  
 The most famous and successful MT targeting compound is Paclitaxel or Taxol. Taxol was 
discovered in the 1960s, isolated from the bark of the Pacific Yew tree, but its complex structure 
and low purification yield left many researchers uninterested (Wani et al. 1971). A decade later, 
pivotal work by Susan Horwitz and her graduate student Peter Schiff demonstrated Taxol acted by 
binding to and stabilizing MTs, unlike any other MT targeting drug to date (Schiff et al. 1979). 
Taxol is still used to treat a variety of cancers such as ovarian, breast, and non-small lung cell 
cancers (Florian and Mitchison 2016).  
 While the success of MT-targeting agents in the clinic should be celebrated, it is interesting 
to note that the reason for their success remains a mystery.  MT-targeting agents are thought to 
function by targeting rapidly dividing cells by interfering with MT and mitotic spindle dynamics, 
leading to mitotic arrest. Indeed, a common side effect associated with taxol treatment is 
neutropenia, demonstrating taxols toxicity to proliferative tissue in the body (Rowinsky et al. 
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1993). However, the proliferation rate of solid tumors that Taxol is commonly used to treat is 
relatively low, begging the question of how Taxol is able effectively stop tumor growth  (Mitchison 
2012). Furthermore, it was demonstrated in samples from breast cancer patients and cell lines that 
clinically relevant Taxol concentrations do not induce mitotic arrest and instead, forced cells to 
undergo mitosis with multipolar spindles (Zasadil et al. 2014). This suggests that the success of 
Taxol is due to its ability to induce chromosome missegregation, leading to cell death. Regardless 
of clinical mechanism, Taxol remains the most successful chemotherapy in history (Walsh and 
Goodman 2010). 
 It is also worth noting that MT-targeting agents do have negative side effects for the 
patients that take them. The most common are neutropenia and peripheral neuropathy (Rowinsky 
et al. 1993). The fact remains that MTs are needed for a variety for cellular functions, and cells 
that rapidly divide such as neutrophils, or rely on their MT network for long distance signaling 
such as neurons, will be negatively affected.   
 
Next Generation Anti-Mitotics  
 To minimize collateral damage, next generation anti-mitotics target proteins with mitotic-
specific functions, such as kinases required for mitotic progression or kinesins that assemble the 
mitotic spindle. From the first category, mitotic kinases such as Aurora A, Aurora B, and Plk1 are 
all current targets for chemotherapeutics and have active clinical trials (clinicaltrials.gov). Aurora 
A and B are kinases vital for mitotic progression, phosphorylating key spindle assembly factors 
and SAC components, respectively (Perez et al. 2015).  The mitotic kinase Plk1 is a workhorse 
kinase during mitosis, playing a role in centrosome maturation, chromosome alignment, and 
cytokinesis (Combes et al. 2017).  
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 The spindle itself is a mitosis specific machine, acting as the mechanical structure that 
supports and drives mitosis forward.  With this in mind, several inhibitors have been discovered 
that target mitotic kinesins that aid in spindle assembly and function. Several inhibitors exist for 
kinesins, but only Eg5 and CENP-E inhibitors have been used in clinical trials, discussed below.  
 The first Eg5 inhibitor discovered was monastrol, named for its ability to cause mono-
asters in mammalian tissue culture cells (Mayer et al. 1999).  In fact, monastrol was the first 
selective kinesin inhibitor to be discovered, kicking off a wave of excitement in both the clinical 
and basic biology fields.   Cell biologists jumped on the opportunity to use K5Is to understand the 
role Eg5 played in spindle assembly, while pharmaceutical companies were hoping to finally have 
found an anti-mitotic that would wreck the spindle without causing neurotoxicity. Several 
pharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, and Merck all had 
competing K5I discovery programs, reflecting the excitement and promise around Eg5 and K5I 
scaffolds. To date, over 50 Phase I & II clinical trials testing different K5Is have been completed 
and millions of dollars have been spent studying and optimizing these compounds (Kozielski 
2012).  Despite their initial promise of becoming a block-buster chemotherapy, K5Is have largely 
failed in the clinic. Some reports documented stabilization of tumor growth, but none reported 
regression in tumor size. Though K5Is are inefficient as a monotherapy, there are currently active 
clinical trials for the treatment of multiple myeloma using the K5I ARRY-520 in combination with 
a proteasome inhibitor (Carfilzomib) or Pomalidomide and Dexamethasone, an anti-angiogenic 
and corticosteroid, respectively. The CENP-E inhibitor GSK-923295 is an allosteric rigor inhibitor 
that has been used in a single Phase 1 clinical trial, where its pharmacokinetics and dose-limiting 
toxicities were reported (Chung et al. 2012).  
20 
 
 Several reasons for K5I failure have been hypothesized. The most obvious reason would 
be development of mutations within the K5I binding site of Eg5, rendering the small molecule 
inactive (Talapatra et al. 2013).  This is a common downfall for several cancer drugs, as the genetic 
instability of tumors allows for selection for resistance mutations (Mansoori et al. 2017).  Another 
possibility, which was discussed earlier, is that the success of anti-mitotics depends on the 
proliferation rate of the target tumor as well as retention time of the small molecule. Monopolar 
spindles have been observed from tumor samples from patients that were administered a K5I, 
indicating that K5Is indeed disrupt spindle assembly (Kantarjian et al. 2012).  Another hypothesis 
is that tumor cells may overcome Eg5 inhibition by employing alternative spindle assembly 
mechanisms. Indeed, work from KIRCs suggests monopolar spindles are an intermediate structure 
in the Kif15-driven spindle assembly pathway (Sturgill and Ohi 2013).  Mechanisms that 
overcome K5I treatment in tissue culture cells involve over expression of Kif15 or expression of 
a MT bundler, thus increasing Kif15s substrate in the cell. In both tumor and non-tumor derived 
cell culture lines, K5I resistance depends on Kif15, regardless of the resistance mechanism 
(Sturgill et al. 2016).  
 
Summary   
  This study strives to understand how Kif15 is regulated both naturally and 
pharmacologically. The first chapter details studies that focus on how Kif15 is regulated by auto-
inhibition and direct interactions with kinesin-binding protein (KBP), a regulatory protein recently 
characterized to bind several kinesins. Understanding how Kif15 is regulated in cells may provide 
potential insights into the mechanisms that drive K5I resistance as well as methods to exploit 
natures regulation for therapeutic use.   
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 The majority of this dissertation focuses on identifying and characterizing small molecule 
inhibitors of Kif15. The drive to discover Kif15 inhibitors is two-fold. First, the clinical potential 
of combining K5Is with a Kif15 inhibitor has been discussed as a method to fully inhibit spindle 
assembly (Kozielski 2012; Sturgill et al. 2016). While this potential is exciting and supported by 
preliminary research, this hypothesis cannot be tested without a Kif15 inhibitor. Second, kinesin 
inhibitors have been instrumental in furthering our understanding of kinesin function. Currently, 
Kif15 silencing by siRNA or knock-out by CRISPR (and other methods) are the only options to 
experimentally disrupt Kif15 activity in cells. While these methods are fundamental for cell 
biology research, they pose several limitations and do not provide the precision of small molecule 
inhibition. Clinical value aside, a small molecule inhibitor for Kif15 will provide a powerful tool 
to study Kif15 activity and function in mitosis.  
 We screened a library of kinase inhibitors with the goal of identifying privilege scaffolds 
for Kif15 inhibition. We identified GW108X, an oxindole kinase inhibitor that inhibits Kif15 
activity in-vitro and blocks spindle assembly when combined with K5Is. A commercially available 
Kif15 inhibitor, Kif15-IN-1, is also characterized and compared to GW108X. Importantly, we 
discovered that GW108X and Kif15-IN-1 are non-ATP competitive and ATP competitive 
inhibitors, respectively. This difference in inhibitory mechanism suggests that these two inhibitors 
are targeting different, druggable sites on Kif15.  
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CHAPTER 2 
 
MATERIALS AND METHODS  
 
Protein Expression and Purification  
His6-GFP-Kif15-FL, His6-Kif15-N700, His6-HSET, Kif18A-N480-GFP-His6, and 
Kif18A-FL-GFP-His6 purifications have been described previously (Norris et al. 2018; 
Reinemann et al. 2017; Stumpff et al. 2011; Sturgill et al. 2014). His6-Kif15-N420 was purified 
identically to His6-Kif15-N700 except that the protein was dialyzed overnight into 10 µM ATP 
before being frozen.  The activity of each His6-Kif15-N420 protein prep was tested by 
approximating the ATP to ADP conversion rate before use in small molecule screening.  In brief, 
a standard curve measuring the luminescence with known ADP:ATP ratios was generated using 
the ADP-Glo assay (described below).  The assay was then run with different concentrations of 
His6-Kif15-N420 and the luminescence values were compared to the standard curve to 
approximate ADP generation.  The concentration of His6-Kif15-N420 that generated ~20-30% 
ATP to ADP conversion rate was used for screening.  
GST-KBP was expressed in BL21DE3 cells with 0.4 mM IPTG overnight at 16ºC.  Cells 
were pelleted and flash frozen in liquid nitrogen and stored at -80ºC. For purification, pellets were 
resuspended in lysis buffer (1xPBS, 500 mM NaCl, 5 mM β-mercaptoethanol (β-ME), 1% NP40 
and protease inhibitors (Complete Protease Inhibitor Cocktail tablets, Sigma-Aldrich).  Lysate was 
incubated with 1 mg/mL of lysozyme for 30 minutes on ice, followed by sonication.  Lysate was 
clarified by centrifugation at 35,000 rpm for 1 hour at 4ºC in a Ti 45 rotor (Beckman). Clarified 
supernatant was incubated with 2 mL of glutathione-agarose (Sigma-Aldrich) for 1 hour at 4ºC 
and washed with ~200 mLs of wash buffer (1xPBS, 500 mM NaCl and 5 mM β-ME).  Protein was 
23 
 
eluted with 1 M Tris (pH 8.0), 3 M KCl and 200 mM glutathione and peak fractions were buffered 
exchanged into storage buffer (10 mM K-HEPES pH 7.7, 100 mM KCl and 1 mM DTT) using a 
PD 10 desalting column (GE Healthcare). Protein concentration was determined using Bradford 
assays and powdered sucrose was added 10% w/v before the protein was aliquoted, frozen in liquid 
nitrogen, and stored in -80ºC.   
 
MT Gliding Assay and Image Analysis 
Flow chambers were assembled using a glass slide, a No. 1.5 glass coverslip and double-
sided tape to create a ~20 µl chamber.  Approximately 1-1.5 µM of His6-Kif15-N700 was 
incubated in the chamber for 3 minutes to allow non-specific absorption of the motor to the 
coverglass surface.  The chamber was then washed with 60 µl of wash buffer (WB, [BRB80, 1 
mM MgATP, 0.5 mg/ml casein]) and then incubated with 1% Pluronic F-127 for 1 minute to 
passivate the surface. The chamber was then washed with 60 µl of WB and then incubated with 
0.5-1 µM of Alexa-594 labelled MTs (1:10, labeled:unlabeled tubulin) for 3 minutes.  Lastly, the 
chamber was washed with 60 µl of flow cell buffer (WB plus 70 mM β-ME, 0.035 mg/ml catalase, 
0.2 mg/ml glucose oxidase, 4.5 mg/ml glucose) and then imaged by epifluorescence microscopy. 
All compounds were added to FCB and then introduced into the flow cell. Images were acquired 
with a Nikon Elements controlled Eclipse 90i (Nikon) equipped with a 60X 1.4 NA (Nikon) 
objective and a Cool Snap HQ2 CCD camera (Roper). Time lapse sequences spanned 2 minutes 
with acquisitions captured every 2 seconds. Image J was used for image analysis and for GW108X, 
GW108X derivatives and Kif15-IN-1 experiments, MT velocity was calculated by measuring the 
distance a MT travelled in 20 seconds.  
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For wash out/wash in experiments, time lapse sequences spanned 5 minutes with 
acquisitions captured every 5 seconds. MT velocity was calculated by measuring the distance the 
MT travelled in 1 minute before wash in, after compound addition, and after wash out.   
MT gliding velocity with KBP was calculated by measuring the distance the MT travelled 
in total during the 2 minute movie (120 seconds). The average velocity of control slides from one 
experimental day was calculated and used to calculate the percent inhibition using the following 
equation,  
% 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = 100 − ((
𝑉𝑥
𝑉𝑢
) ∗ 100) 
where Vx is the velocity of a single MT and Vµ is the average velocity of control MTs from that 
experimental day.  
 
ATPase Assay Screening Conditions 
The Promega ADP GloTM Kinase Assay kit was used to detect the ATPase activity of His6-
Kif15-N420 and was adapted for use in high throughput format.  Uniformity and reproducibility 
of the assay was evaluated by plating positive and negative reactions (+/- ATP, respectively) 
containing His6-Kif15-N420, MTs and reaction buffer (10 mM K-HEPEs pH 7.7, 100 mM KCl, 1 
mM DTT, 1 mM MgCl2, 20 µM taxol) in every other well of a 384 well plate. Z-factor (Z’) was 
calculated as follows where p is positive control and n is negative controls:  
𝑍′ = 1 −
3(𝜎𝑝 +  𝜎𝑛)
|𝜇𝑝 − 𝜇𝑛|
 
For screening the GlaxoSmithKline Published Kinase Inhibitor Set (Drewry et al 2014), 10 
µM of compound was shot into a 384 well plate (Greiner Bio-One) and incubated with 30 nM of 
His6-Kif15-N420 + 5 µM MTs for 15 minutes.  The reaction was then incubated with 10 µM ATP 
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for 20 minutes to stimulate the ATPase activity of His6-Kif15-N420. Next, the kit reagent ADP-
Glo was added to stop the ATPase reaction and deplete unconsumed ATP.  After 40 minutes of 
incubation with ADP-Glo, the second kit reagent, Kinase Detection Reagent, was added to convert 
the ADP generated by His6-Kif15-N420 to ATP.  This ATP is then used to fuel a luciferase reaction 
and after 30 minutes, luminescence is measured using a luminometer (BioTek).  Positive and 
negative control reactions were incubated with DMSO and either contained or lacked ATP, 
respectively. All reactions were performed at room temperature.  Concentration response curves 
were performed as described above, except with varying concentrations of compounds.  
Analysis of experimental days was performed in Waveguide (Vanderbilt HTS facility).  To 
ensure assay quality, the Z’ and coefficient of variation (% CV) for the positive, negative and 
compound wells were calculated for each plate.  The % inhibition, Z-score and B-score were 
calculated for each compound.  The top 5 hits from the screen reproducibly exhibited % inhibition 
> 60%, Z-score < -3 and B-score < -8.   
 
Steady State ATPase Assay 
Enzyme-coupled ATPase rates were quantified by NADH absorbance decay at 340 nm 
using a Multi-Mode Micro Plate Reader (Molecular Devices Flexstation 3), with 10-20 nM active 
dimeric His6-Kif15-N700 motors. Motors and inhibitors were pre-incubated for 30 minutes to 
ensure steady state before ATP was added to initiate the ATPase reaction. Velocities were fit to an 
unweighted Michaelis-Menten curve, and these fitted KM and kcat were used to plot a line to the 
data in the Lineweaver-Burk plots.  
 
 
26 
 
Cell Culture, Transfections, and Immunoblotting  
TP53-/- RPE-1 cells  (Izquierdo et al. 2014, a gift from Bryan Tsou, Memorial Sloan 
Ketterling Cancer Center) were cultured in DMEM containing 10% FCS, penicillin and 
streptomycin.  KIRC-1 cells were cultured in the same media with the addition of 10 µM STLC 
(Sigma-Aldrich).  
siRNA transfections were performed using HiPerfect (QIAGEN). The following Kif15 
siRNA was used: 5’ – GGACAUAAAUUGCAAAUAC – 3’ (Dharmacon).   
TP53-/- RPE-1 and KIRC-1 cells were grown in a 6-well dish (Denville) and were washed 
with PBS, trypsinized, and were resuspended and incubated in lysis buffer (Roche Protease 
Inhibitor cocktail tablet, 1% NP-40, 6 mM Na2HPO4, 4 mM NaH2PO4, 150 mM NaCl, 2 mM 
EDTA, 50 mM NaF, 4 µg/mL leupeptin, 0.1 mM Na3VO4) for 15 minutes on ice. Extracts were 
clarified at 4ºC for 15 mins at 13K rpm and diluted 1:5 in 5x sample buffer (SB, 100 mM Tris-Cl, 
pH 6.8, 4% SDS, 20% glycerol, 200 mM DTT and 200 µg/ml bromophenol blue) and boiled. 
Samples were loaded at 25-27 µg total protein onto a TGX Stain-Free 10% Acrylamide gel (Bio-
Rad), resolved by SDS-PAGE and transferred to a PVDF membrane for immunoblotting.  
PVDF membranes were blocked with Odyssey blocking buffer (LI-COR Biosciences) 
diluted 1:1 in PBS for 1 hour at RT and probed with α-Kif15 at 1 µg/ml, DM1α (Abcam) at 1:5000, 
or mouse-KBP (Abnova) 1:1000 overnight at 4ºC (Sturgill and Ohi 2013).  Membrane was washed 
3x for 10 minutes with PBST and incubated with secondary antibodies conjugated to Alexa Fluor 
700 (Invitrogen) or IRDye-800 (LI-COR) at 1:5000 for 1 hour at RT. Membrane was washed with 
PBST and PBS and bound antibodies were detected using an Odyssey fluorescence detection 
system (Mandel Scientific).  
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Generation of K5I-Resistant RPE-1 Cells  
We generated K5I-resistant TP53-/- RPE-1 cells as previously described (Sturgill and Ohi 
2013). The KIRC-1 cell line is a single clonal isolate. The properties of KIRC-1 and other K5I-
resistant TP53-/- RPE-1 isolates will be described elsewhere.  
 
Co-pelleting Assays  
 
MT-co-pelleting was performed by incubating 700 nM of KIF18A-N480-GFP-His6 or 1 
µM of His6-KIF15-N420 with 2 µM of GST-KBP in reaction buffer (10 mM K-HEPES pH 7.7, 
50 mM KCl, 10 mM DTT, 1 mM MgCl2 and 20 µM taxol (Sigma-Aldrich)) for 10 minutes at room 
temperature to promote their interaction. KIF18A-N480-GFP-His6, His6-KIF15-N420, and GST-
KBP were clarified by spinning at 90k rpm for 10 minutes at 4ºC prior to use in assay.  Next, 1 
µM of taxol stabilized MTs and 1 mM AMPPNP (Sigma-Aldrich) was added to each reaction and 
incubated at room temperature for 15 minutes.  The reaction was then spun over 150 µL of sucrose 
cushion (10 mM K-HEPES pH 7.7, 50 mM KCl, 20 µM taxol, 40% w/v sucrose) at 60k rpm for 
20 minutes at 26ºC.  50 µL of supernatant was removed and mixed 1:1 with 2x sample buffer.  The 
remaining supernatant was removed and the supernatant/cushion interface was washed 2x with 
reaction buffer. The cushion was then removed and the pellet was gently washed with reaction 
buffer before being resuspended in 100 µl of 1x SB.  Both supernatant and pellet samples from 
each reaction was boiled, vortexed and 30 µL was run on a 10% SDS-PAGE gel.  The gel was 
then stained with Coomassie for ~30 minutes and destained overnight before imaging. ImageJ was 
used to quantify the integrated intensity of each protein band.  Integrated intensity of the 
supernatant and pellet lanes for each reaction was combined to give yield a total protein integrated 
intensity value, which was used to calculate the percent of protein in the supernatant. 
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KIF18A-FL-GFP-His6 and His6-GFP-KIF15-FL co-pelleting experiments were performed 
as described above, except proteins were detected using Western blots instead of Coomassie. For 
KIF18A-FL-GFP-His6 experiments, 120 nM of kinesin and 342 nM of GST-KBP was used. For 
His6-GFP-KIF15-FL experiments, 135 nM of kinesin and 384 nM of GST-KBP was used. Blots 
were cut ~70 kDa and the top portion was probed with rabbit-His (MBL, 1:1000) and mouse-KBP 
(Abnova, 1:1000) and the bottom with  tubulin (DM1, Abcam). 
 
Co-Immunoprecipitation Assays 
Glutathione agarose slurry (Pierce) was washed with binding buffer (BB, 10 mM K-
HEPES pH 7.7, 50 mM KCl, 1 mM DTT, 100 µM ATP, 0.1% NP-40) and incubated with 250 nM 
GST-KBP for 1 hour at 4ºC with rotation. Agarose was then washed 3x with BB and incubated 
with 20 mg/mL BSA for 30 minutes at 4ºC with rotation. Agarose was washed 3x with BB and 
incubated with 50 nM KIF18A-N480-GFP-His6, KIF18A-FL-GFP-His6, His6-KIF15-N420 or 
His6-GFP-KIF15-FL for 1 hour at 4ºC with rotation. Agarose was pelleted and supernatant was 
removed and saved, and the agarose pellet was resuspended in BB. Agarose was then washed 5-
10x in BB. After washing, agarose was resuspended in 1x sample buffer (50 mM Tris-Cl, pH 6.8, 
2% SDS, 6% glycerol, 1% βME and 200 µg/mL bromophenol blue) and boiled. Samples were 
loaded onto a TGX Stain-Free 10% Acrylamide gel (Bio-Rad), resolved by SDS-PAGE and 
transferred to a PVDF membrane for immunoblotting.  
PVDF membranes were blocked with Odyssey blocking buffer (LI-COR Biosciences) 
diluted 1:1 in PBS for 1 hour at RT and probed with rabbit-His (MBL, 1:1000) and mouse-KBP 
(Abnova, 1:1000) overnight at 4ºC. Membrane was washed 3x for 10 minutes with PBST and 
incubated with secondary antibodies conjugated to Alexa Fluor 700 (Invitrogen) or IRDye-800 
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(LI-COR) at 1:5000 for 1 hour at RT. Membrane was washed with PBST and PBS and bound 
antibodies were detected using an Odyssey fluorescence detection system (Mandel Scientific).  
 
Spindle Assembly Assay and Fixed-Cell Imaging 
For spindle assembly assays, TP53-/- RPE-1 and KIRC-1 cells were treated with 25 µM 
GW108X, Kif15-IN-1 or DMSO for 24 hours.  Cells were fixed in methanol at -20ºC for 10 
minutes and then labeled with the following primary antibodies: FITC-conjugated mouse anti-α-
tubulin (DM1α; Sigma-Aldrich), 1:500; and rabbit anti-Kif15 (α-Kif15), 1:2000. Secondary 
antibodies conjugated to Alexa-594 (Invitrogen) were used at 1:500. Fixed cells were incubated 
with primary and secondary antibodies for 1 hour each at room temperature. DNA was 
counterstained with 5µg/ml Hoechst 33342 and stained cells were mounted in Prolong Gold 
(Invitrogen).  
Images were acquired using a 60X 1.4 NA objective (Olympus) on a DeltaVision Elite 
imaging system (GE Healthcare) equipped with a Cool SnapHQ2 charge-coupled device (CCD) 
camera (Roper). Optical sections were collected at 200 nM intervals and processed using ratio 
deconvolution in SoftWorx (GE Healthcare).  Further image processing was done in ImageJ. 
Acquisition parameters were same across cell lines and conditions.  
For Kif15 and tubulin spindle intensities, an oval ROI was drawn around the spindle to 
measure the integrated fluorescence of a sum intensity projection for both the tubulin and Kif15 
channels.  Four smaller ROI ovals were made around the spindle to measure background 
fluorescence.  The four background measurements were averaged and subtracted from the spindle 
ROI intensity for their respective channel. These values were used to calculate the Kif15:tubulin 
ratio.  
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For spindle collapse assays with KBP-OE, cells were collected in G2 overnight with 9 µM 
RO-3306 (Axxora), washed 5X with DMEM supplemented with FBS and pen/strep, then treated 
for 90 minutes with 5 µM MG132, followed by 90 minutes with 5 µM MG132 + 10 µM DMSO 
or 10 µM STLC (Sigma-Aldrich). Cell fixation is the same as described above.  
 
Compound Synthesis Information 
Complete description of compound synthesis and characterization have been previously 
published (Dumas et al. 2018).  All reactions requiring anhydrous conditions were conducted in 
flame dried glass apparatus under an atmosphere of argon. THF, Et2O, CH2Cl2, DMF, benzene and 
acetonitrile were dried by passage through an activated alumina column under argon. DMSO was 
distilled from CaH2 at 15 mm Hg and stored over activated 4Å molecular sieves. Anhydrous 
MeOH was freshly distilled from calcium hydride. Preparative chromatographic separations were 
performed on silica gel (35-75 μm); reactions were followed by TLC analysis using silica plates 
with fluorescent indicator (254 nm) and visualized with a UV lamp or phosphomolybdic acid. All 
commercially available reagents were purchased from TCI or Aldrich and used as received unless 
stated otherwise. Optical rotations were measured with a polarimeter using a 1 mL capacity cell 
with 1 dm path length. Infrared spectra were recorded using a thin film supported on KBr discs or 
dispersed in a KBr pellet. 1H and 13C NMR spectra were recorded in Fourier transform mode at 
the field strength specified on either a 300 or 400 spectrometer. Spectra were obtained on CDCl3 
or DMSO-d6 solutions in 5 mm diameter tubes, and chemical shifts in ppm are quoted relative to 
the residual signals of chloroform (δH 7.26 ppm, or δC 77.0 ppm). Multiplicities in the 1H NMR 
spectra are described as: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad; 
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coupling constants are reported in Hz. Low (MS) and high (HRMS) resolution mass spectra are 
reported with ion mass/charge (m/z) ratios as values in atomic mass units. 
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Introduction 
 
 Kinesins are molecular motors that use ATP hydrolysis to drive mechanical processes 
inside cells. Regulation of these enzymes is crucial to prevent hyperactive kinesin activity and 
prevent futile ATP hydrolysis. As described in the introduction, cells employ a variety of methods 
to regulate the ATPase cycle of kinesin family members, including autoinhibition.  Kif15 uses 
autoinhibition to regulate both its activity and spindle localization (Sturgill et al. 2014).  The region 
of inhibition has been broadly narrowed down to the last 400 AAs, but the specific residues 
required for inhibition remain unknown.  Understanding Kif15 autoinhibition is important not only 
to understand how the activity of this motor is regulated, but to gain a deeper insight into the Kif15 
inhibitor designed by nature.  
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 A recent study demonstrated that the regulatory protein kinesin-binding protein (KBP) can 
bind the motor domain of several human kinesins, including the mitotic kinesins Kif15 and Kif18A 
(Kevenaar et al. 2016). KBP was first identified in patients with Goldberg-Shprintzen syndrome, 
a disorder that effects the central and enteric nervous system (Alves et al. 2010; Brooks et al. 
2005).  Kevenaar et al focused on the interaction between KBP and Kif1A, a kinesin-3 family 
motor involved in neuronal transport. Mechanistically, KBP regulates Kif1A by interfering with 
the motors ability to bind MTs.  Previous studies with Kif1B, another kinesin-3 family member, 
report that MT binding and motility of the kinesin is increased in the presence of KBP (Wozniak 
et al. 2005).  Additionally, a recent study that examined the interaction between Kif15 and KBP 
reported that KBP promotes Kif15’s localization to the spindle and that KBP knockdown 
comprises K-MT stability and chromosome alignment (Brouwers et al. 2017).  While the function 
of KBP between these studies remains contradictory, it has become clear that KBP-motor 
interactions must be addressed when considering regulation of the kinesins predicted to interact 
with KBP (Kevenaar et al. 2016).   
 However, the ability of KBP to regulate the mitotic motor Kif18A remains unknown. 
Kif18A is a kinesin-8 family member that is enriched at the tip of K-MTs and helps regulated K-
MT length and is required for chromosome congression (Mayr et al. 2007; Stumpff et al. 2008). 
Kif18A regulates K-MT dynamics by suppressing K-MT oscillations, thus ensuring that 
chromosomes remain within the metaphase plate (Du e al. 2010).  Furthermore, while it is clear 
that Kif15 is self-regulated, how KBP could be affecting this regulation remains an important 
question. To understand KBPs interaction and regulation of the mitotic motors Kif15 and Kif18A, 
we employed mostly in vitro assays to ask if and how KBP effects the activity of these motors.  
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C-terminal Inhibition of Kif15 Resides Within its Last 100 Amino Acids  
 Previous work has demonstrated that Kif15 is self-repressed by a region in its C-terminal 
tail called Coil-2 (Sturgill et al. 2014).  Coil-2 contains 400 amino acids (AA) and is predominately 
a coiled-coil, with a leucine zipper (LZ) motif at the end of the C-terminus (Figure 3.1 A, Boleti 
et al. 1996; Sturgill et al. 2014).  To narrow down the region required for auto-inhibition, sequential 
protein fragments containing 100 AA were purified for use in the MT gliding assay.  A previously 
characterized truncated Kif15 construct, Kif15-N700, was used for all MT gliding assays (Sturgill 
et al. 2014).  The most C-terminal protein fragment F4 inhibited Kif15-N700 MT gliding in a dose-
dependent manner (Figure 3.1 B).  This inhibition was specific to F4, as F3 was unable to inhibit 
Kif15-N700 MT gliding even at high concentrations (Figure 3.1 B).  
 To confirm in cells, deletion constructs lacking either the C-terminal 100 AA or LZ (GFP-
Kif15-Δ100, GFP-Kif15-ΔLZ) were generated and expressed in HeLa cells. Even in the presence 
of AMPPNP, Kif15-FL remains auto-inhibited and does not bind MTs (Sturgill et al. 2014, Figure 
3.1 C).  In contrast, both Kif15-Δ100 and Kif15-ΔLZ permit binding to interphase MT, suggesting 
relief of auto-inhibition (Figure 3.1C).  Interestingly, removal of the LZ allows Kif15 to bind 
interphase MTs, but to a lesser extent when compared to Kif15-Δ100.  This suggests that the LZ 
contributes to auto-inhibition, but that other sequences within the coiled-coil are required for 
complete inhibition of the motor.  
 
KBP Inhibits Kif15 and Kif18A MT Gliding 
To understand if KBP can regulate Kif15 and Kif18A activity, we analyzed MT gliding of 
the dimeric motor constructs Kif15-N700 and Kif18A-N480 in the presence of bacterially purified 
GST-KBP. Using the same motor concentration, 250 nM GST-KBP inhibited Kif18A MT gliding 
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by 90% and Kif15 MT gliding by 76% (Figure 3.2 B & D). This difference of inhibition is 
visualized in Figure 3.2 A and C, which shows the first and last frames of representative movies 
pseudo colored in red and green, respectively. Addition of 500 nM GST-KBP increases inhibition 
of Kif15 MT gliding slightly, increasing from 75% to 82%. The high % inhibition observed with 
Kif18A-N480 suggests that KBP may have a higher affinity for Kif18A over Kif15. 
 
Figure 3.1 C-terminal amino acids required for Kif15 auto-inhibition. A) Schematic of Kif15-FL, 
Kif15-Δ100, Kif15-ΔLZ constructs and Coil-2 tail fragments. Blue highlights N-terminal motor 
domain, green highlights Coil-1, red highlights the C-terminal region Coil-2 and grey represents the 
leucine sipper. Kif15-Δ100 lacks the last 128 AAs and Kif15-ΔLZ lacks the last 30 AAs of Kif15s C-
terminal tail. B) Average MT gliding velocity of Kif15-N700 in the presence of Fragment 4 and 
Fragment 3. C) Representative single focal planes of HeLa cells expressing Kif15-FL (left), Kif15-
Δ100 (middle) or Kif15-ΔLZ (right) infused with AMPPNP. Corresponding zoomed images are below 
and show the merged, tubulin, and Kif15 channels. Scale bar, 10 µm.  
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 KBP Binds Directly to Kif15 and Kif18A  
 To determine if KBP directly interacts Kif15 and Kif18A, we performed co-
immunoprecipitation of purified GST-KBP with the dimeric motor constructs Kif15-N420 and 
Kif18A-N480. First, glutathione agarose beads were functionalized with GST-KBP and incubated 
with or without Kif15-N420 or Kif18A-N480. Both Kif15-N420 and Kif18A-N480 only pellet 
when GST-KBP is present, indicating a direct interaction between KBP and the motor domains of 
these constructs (Figure 3.3 A & B). We next tested the ability of KBP to bind the physiologically 
relevant full length (FL) constructs of Kif15 and Kif18A.  In the presence of GST-KBP, Kif18A-
FL completely pellets with the beads (Figure 3.3 C).  Kif15-FL is autoinhibited by its C-terminal 
Figure 3.2 KBP inhibits Kif18A and Kif15 MT gliding. A) Representative fields from MT gliding assay with 
Kif18A-N480 showing the first frame (red) and last frame (green) of MTs in the presence or absence of GST-
KBP. B) Quantification of percent inhibition of MT gliding for Kif18A-N480 alone (n = 95) or with 100 nM (n = 
147) or 250 nM (n = 123) GST-KBP. C) Representative fields from MT gliding assay with Kif15-N700 showing 
the first frame (red) and last frame (green) of MTs in the presence or absence of GST-KBP. D) Quantification of 
percent inhibition of MT gliding for Kif15-N700 alone (n = 76) or with 250 nM GST-KBP (n = 125) or 500 nM 
GST-KBP (n = 92). N = total number of MTs measured from triplicate independent experiments. Scale bars, 20 
µm.  
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tail and not surprisingly, KBP is unable to interact with the Kif15-FL motor domain (Figure 3.3 
D). 
 
Figure 3.3 Direct interaction between KBP and the motor domains of Kif15 and Kif18A. 
Representative western blots from co-IP experiments using various Kif18A and Kif15 purified proteins. For 
all experiments, 50 nM of kinesin and 250 nM KBP was used. A) Co-IP with Kif18A-N480 and GST-KBP. 
B) Co-IP with Kif15-N420 and GST-KBP. C) Co-IP with Kif18A-FL and GST-KBP. D) Co-IP with Kif15-FL 
and GST-KBP. All blots were probed with antibodies targeting 6xHis (α His) and KBP (α KBP). 
 
KBP Blocks MT Binding of Kif15 and Kif18A 
After confirming direct interaction between KBP and the motor domains of Kif15 and 
Kif18A, we next tested if this interaction blocked MT binding using the MT co-pelleting assay. 
We continued to use the minimal dimeric motor constructs which lack secondary MT binding sites 
for both kinesins, ensuring any MT binding effects are due to KBP:motor interactions.  In control 
conditions, 9% of Kif18A-N480 protein is detected in the supernatant, with the majority of protein 
pelleting with the MTs.  In the presence of KBP, 86% of Kif18A-N480 is now detected in the 
supernatant (Figure 3.4 A). Interestingly, even though KBP is able to interact with full length 
Kif18A (Kif18A-FL, Figure 3.3 C), it is unable to shift Kif18A-FL to supernatant in the co-
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pelleting assay (Figure 3.5 A). This is likely due to secondary MT binding elements within 
Kif18A’s tail (Weaver et al. 2011).  
The MT co-pelleting assay is not ideal for probing pellet to supernatant shifts for Kif15.  
Even in the presence of AMPPNP, 48 ± 2% of Kif15-N420 is reproducibly found in the 
supernatant. This result suggests that Kif15-N420 likely has a low Kon rate for MTs, which is 
further supported by this constructs inability to glide MTs in the MT gliding assay (Sturgill and 
Dumas, unpublished). Regardless, there was a significant shift of Kif15-N420 to the supernatant 
in the presence of KBP, reproducibly increasing to 67 ± 2% (Figure 3.4 B). As predicted, Kif15-
FL was unable to bind MTs in vitro (Figure 3.5 B).  
Figure 3.4 KBP interferes with Kif18A-N480 and Kif15-N420 MT binding. A) Results from co-pelleting assay 
with Kif18A-N480 or B) Kif15-N420 in the presence or absence of KBP and/or MTs. P, pellet; S, supernatant. 
Bottom: representative Coomassie gels Top: quantification of percentage of kinesin motor present in supernatant 
fractions. Data was obtained from three independent experiments. ns, not significant, ****, adjusted P < 0.0001, 
*, adjusted P = 0.031 with 95% confidence interval by one-way ANOVA with Tukey’s multiple comparisons test. 
Error bars represent SEM.  
39 
 
 
Figure 3.5 Full length kinesin motors display complex KBP regulation. A) Co-pelleting assay with 
Kif18A-FL, KBP, and/or MTs. Image is western blot probed with antibodies targeting 6xHis (α His), KBP (α 
KBP), and tubulin (DM1α). B) Co-pelleting assay with Kif15-FL, KBP and/or MTs. Image is western blot 
probed with antibodies targeting 6xHis (α His), KBP (α KBP), and tubulin (DM1α). 
 
KBP Overexpression Prevents Kif15-Driven Spindle Stabilization  
 We next asked if KBP had an effect on Kif15 function in cells. In HeLa cells, Kif15 is 
required for spindle bipolarity maintenance in the absence of Eg5. HeLa metaphase spindles 
remain bipolar when treated with the Eg5 inhibitor STLC but collapse to monopoles when Kif15 
is knocked down via siRNA (Tanenbaum et al. 2009).  To determine if KBP interferes with Kif15 
mediated spindle stability, spindle structures were scored from HeLa cells transfected with 
mCherry alone or mCherry-KBP and whose metaphase spindles were treated with DMSO or 
STLC. The percent of monopolar spindles increased twofold in cells expressing mCherry-KBP, 
indicating KBP interferes with Kif15 mediated spindle bipolarity (Figure 3.6).  Endogenous Kif15 
remains localized to the metaphase spindle when KBP is over expressed (OE) due to its second 
non motor MT binding site (Malaby et al. 2019). Though Kif15 localization is not severely 
disrupted when KBP is OE, an increase in monopolar spindles upon STLC addition indicates that 
KBP is indeed blocking motor MT binding, rendering Kif15 unable to resist inward directed forces 
that cause spindle collapse.  
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Figure 3.6 KBP overexpression inhibits Kif15-driven spindle stabilization. A) Schematic of spindle 
collapse assay. B) Metaphase cells expressing mCherry (mCh) only or mCh-KBP treated with DMSO or 
STLC. Scale bar, 10 µm. C) Quantification of the percentage of mitotic cells with monopolar spindles, 
normalized to the DMSO condition. Error bars represent SD. Data was obtained from three independent 
experiments with the following cell numbers: mCh only DMSO (103), mCh only STLC (134), mCh-KBP 
DMSO (200), and mCh-KBP STLC (269). **, adjusted P = 0.0058 with 95% confidence interval by two-way 
ANOVA with Tukey’s multiple comparisons test.  
 
Discussion 
 The creation and maintenance of the mitotic spindle is a highly controlled process that 
relies on the precise regulation of force generating motors to achieve steady state (Dumont and 
Mitchison 2009). Metaphase spindles are dynamics structures yet they reach a stable, steady state 
length. This steady state is crucial for the integrity of the spindle and mitosis itself, with any 
imbalance leading to cell division failures. Cells must have reliable methods to control the activity 
of force generating motors regulating the spindle to ensure bipolarity and mitotic success. This 
reliance on the precise regulation of molecular motors seems risky, and indeed, protein 
concentration can vary between cells up to 30% (Sigal et al. 2006).  Changes in the concentration 
of a mitotic motor puts the cell at risk for loss of spindle steady state.  To overcome these 
fluctuations in protein levels, we hypothesize that KBP acts as a “buffer” within the cell and 
provides fine tuning of mitotic kinesin activity.  Our data confirms that KBP is able to bind and 
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regulate Kif15 and Kif18A activity. Though the data is not shown here, our recent publication in 
collaboration with the Stumpff lab demonstrates that altered KBP expression in cells disrupts the 
activity of both motors, leading to chromosome alignment defects and lagging chromosomes 
(Malaby et al. 2019).    
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Introduction 
Small molecule screening is a popular method to discover target compounds for either tool 
or therapeutic usage. Screening thousands of compounds is a viable option for targets with little 
or no structural data and is widely an unbiased approach.  Indeed, large small molecule screens 
have led to the discovery of several kinesin inhibitors (Catarinella et al. 2009; Mayer et al., 1999; 
Qian et al., 2010).  Small molecule screens can be broken down into two general categories: cell-
based phenotypic or biochemical target-based assays (Coussens et al. 2017).  Cell-based assays 
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rely on a predictable phenotype to score compound effectiveness and due to their unbiased nature, 
it can take months to discover the cellular target of the compound. Alternatively, target based 
approaches utilize an in-vitro assay that contains purified components of the target of interest.  
Downsides of this approach stem from the uncertainty of cell permeability properties of the lead 
compounds and their ability to reach the desired target inside cells. With these considerations in 
mind, and our ability to purify active Kif15 constructs from bacteria, we decided to pursue small 
molecule inhibitors of Kif15 using a target-based approach.  
 Kinases are a highly targeted group of enzymes for cancer therapeutics due to their diverse 
roles in cellular signaling pathways that stimulate cell proliferation and survival (Manning et al. 
2002).  There are currently over three thousand ongoing Phase I-III clinical trials for new kinase 
inhibitors and several pharmaceutical companies have devoted departments for kinase discovery 
research (Bhullar et al. 2018).  As such, kinase inhibitor libraries are widely available to research 
institutions and offer a unique opportunity for investigators interested in targeting proteins that 
hydrolyze ATP. Kinesins also hydrolyze ATP, but instead of transferring the phosphate to a 
substrate, these enzymes translate ATP hydrolysis into mechanical movement. We took advantage 
of the kinase inhibitor resources at Vanderbilt University and hoped to identify a privileged 
scaffold that inhibited Kif15.  
 
Assay Quality Conditions 
To search for Kif15 inhibitors, we used an in-vitro ATPase assay with purified components. 
The luminescence-based ADP-GloTM Kinase assay was chosen for its low assay volume and ability 
to detect low concentration of ATP (Zegzouti et al. 2011, Figure 4.1 A).  To select for compounds 
that bind to the motor domain of Kif15, we used the dimeric motor construct Kif15-N420.  Like 
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other kinesins, Kif15-N420 required the presence of MTs to stimulate ATPase activity.  To test 
the uniformity and reproducibility of the assay conditions, described below, positive (+ ATP), 
negative (- ATP), and control compound (VU0656487) reactions with Kif15-N420 were plated 
every third row (Figure 4.1 B). During preliminary screens, VU487 was confirmed to inhibit 
Kif15-N420, but its lipid like structure deemed it unlikely to be a true inhibitor and instead was 
used as a control for assay variability (Figure 4.1 C). Compound concentration was set to 10 µM 
and was incubated with 30 nM of Kif15-N420 + 5 µM MTs for 15 minutes. The reaction was then 
incubated with 10 µM ATP for 20 minutes to stimulate the ATPase activity of Kif15-N420. Next,  
Figure 4.1 Testing ADP-Glo ATPase assay conditions. A) Schematic of the ADP-Glo assay used to 
measure Kif15-N420 ATPase activity. Kif15-N420 is incubated with microtubules for 20 minutes (Step 1) 
and hydrolyzes ATP to ADP (Step 2). ADP-Glo reagent is added to quench the reaction and deplete 
remaining ATP (Step 3). Kinase detection reagent is added (Step 4) to convert ADP to ATP, which drives 
luciferase activity (Step 5). Luminescence signal directly correlates with ATPase activity of Kif15-N420. B) 
Schematic of plate map used for Triple Checkerboard testing. Red, green, and blue indicate negative (-
ATP), positive (+ ATP) and control (VU487) reactions, respectively. C) Structure of VU0656487. D) 
Representative Triple Checkerboard raw luminescence values from single assay plate.  
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kit reagents were added as described in the Materials and Methods and luminescence was measured 
(Figure 4.1 A).  Using the positive and negative controls, the Z-factor (Z’) was calculated to be 
0.75 (Table 4.1).  Z’ is common statistical measure of assay quality and a Z’ > 0.5 is considered a 
robust assay (Zhang et al. 1999).  Furthermore, we found the % CV of the positive, negative and 
control compounds reactions were all be below 10, indicating little variation (Figure 4.1 D & Table 
4.1). 
 
Screening the GlaxoSmithKline Published Kinase Inhibitor Set   
 To identify chemical scaffolds that target Kif15 as a starting point for tool compound 
development, we screened the GlaxoSmithKline (GSK) Published Kinase Inhibitor Set (PKIS). 
The PKIS is a panel of kinase inhibitors made publicly available to researchers to stimulate 
development of tools that inhibit untargeted kinases within the kinome (Knapp et al. 2013). The 
PKIS was screened in duplicate and the compounds were randomized in the assay plates each day 
(Figure 2 A & B).  
 
Figure 4.2 Screening the GSK PKIS. Luminescence signal directly correlates with ATPase activity of 
Kif15-N420. A) Day 1 and B) Day 2 raw luminescence values from GSK PKIS screened in duplicate.  
Compounds were randomly distributed in the assay plate on both screening days to account for any plate 
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effect. Positive and negative controls are Kif15-N420 + MTs +/- ATP, respectively. Highlighted in green and 
blue is GW108X and VU669 (Figure 4.3). 
 
Experiment Z-factor (Z’) CMPD 
% CV 
Negative 
% CV 
Positive 
%CV 
Triple Checkerboard 0.75 8 5 6 
GSK – Day 1 0.74 13.6 2.76 6.18 
GSK – Day 2 0.73 12 2.68 7.04 
Table 4.1 Statistical analysis of assay development and screening conditions.   
 
The % inhibition, Z-score, and B-score was calculated for each compound on each 
screening day (see Materials and Methods) and the top 10 compounds between the two screening 
days were cherry picked for concentration response analysis (Figure 4.3 & 4.5). The top five 
compounds from the screen reproducibly exhibited a % inhibition > 60%, Z-score < -3 and B-
score < -8 (Figure 4.3). These top five compounds were further characterized for their ability to 
inhibit Kif15 using the MT gliding assay. For these assays, we used Kif15-N700, a longer construct 
that robustly glides MTs (Sturgill et al. 2014). The two oxindoles, VU674 (herein called GW108X) 
and VU669, significantly inhibited Kif15 MT gliding (Figure 4.4).  Both compounds contain an 
oxindole core and a halogenated phenol ring on the right-hand side of the molecule. They differ 
most at the 5-position of the oxindole, with GW108X being an acylfuran and VU669 being an 
iodide (Figure 4.3). GW108X and VU669 were first described as potent c-Raf1 inhibitors and have 
since been extensively characterized by GSK, with GW108X reported as being a promiscuous 
kinase and GPCR inhibitor (Elkins et al. 2016; Lackey et al. 2000; Richters et al. 2015).  We 
decided to pursue GW108X for further analysis because of its sub-micromolar IC50 (Figure 4.3). 
Furthermore, the inhibitory activity of GW108X against Kif15 was scored by calculating the 
velocity of MT gliding over a range of inhibitor concentrations to generate a concentration 
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response curve (CRC). The IC50 using this assay was 734 nM, similar to that calculated using the 
ATPase assay (Figure 4.4 B).  
 
Figure 4.3. Summary of the top five compounds from PKIS screen. Compound name, structure, average % 
inhibition between two GSK screening days, Z-Score, B-Score, and IC50 of top five compounds from GSK screen. 
Graph shows concentration response curve (CRC) generated from the ATPase assay, developed from 10 
concentrations from 30 to 0.001 M. Each concentration was repeated in triplicate. Error bars show SEM. 
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First Round of Structure-Activity Relationship (SAR) Analysis 
 To probe the relationship between structure and Kif15 inhibition activity of GW108X, we 
synthesized a small library of derivatives with modifications to both the furan and phenol regions 
of the molecule. To start, a set of five compounds was synthesized that contained domain swaps 
between GW108X and VU669 (compounds 2 & 5) or contained different halogens on the ortho 
position of the phenol (compounds 1, 3 & 4). To compare the activity of these GW108X 
derivatives, we tested their ability to inhibit Kif15 MT-gliding at 750 nM, roughly the IC50 of 
GW108X (Figure 4.6).  The halogens in the ortho position of the phenol may provide opportunities 
for formation of both hydrogen and halogen bonds with biomolecules. Owing to their importance, 
compounds 1, 2 and 3 displayed a structure activity relationship that correlated with halogen size 
(Figure 4.6). The Kif15 inhibition activity of the compound improved as the halogen size increased 
from fluorine to bromine, with 2 inhibiting MT gliding by 65%. The larger iodines within 3, 
however, were not well tolerated, and none of the compounds showed percent inhibition 
significantly different than that of GW108X.  Not surprisingly, the compounds that resembled 
Figure 4.4. Characterization of top five compounds in the MT gliding assay and IC50 of GW108X. Top 
five compounds from Figure 4.3 analyzed using the MT gliding assay at 30 M. Data is the average MT 
gliding velocity of Kif15-N700 with each compound. Every compound was tested in triplicate the n 30, except 
VU724, which was tested in duplicate with an n  20. C) CRC generated from the MT gliding assay, 
developed from 12 concentrations from 10 to 0.2 M. 
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VU669 and contained an iodine instead of a furan (4 and 5), did not significantly inhibit Kif15 in 
the gliding assay (Figure 4.6). 
 
 
Figure 4.5 Summary of lower scoring compounds (from top 10) from PKIS. Compound name, 
structure, average % inhibition between two GSK screening days, Z-Score, B-Score, and IC50 of bottom 
five compounds from GSK screen. Graph shows concentration response curve (CRC) generated from the 
ATPase assay, developed from 10 concentrations from 30 to 0.001 M. Each concentration was repeated 
in triplicate. Error bars show standard error of the mean (SEM). 
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Figure 4.6 SAR analysis for GW108X derivatives. Compound structures from the first round of SAR 
analysis of GW108X derivatives. Data is the average microtubule gliding velocity of Kif15-N700 with each 
compound tested at 750 nM. Every compound was tested in triplicate with n ≥ 30 measurements for each 
replicate, except 3, which was tested in duplicate. Error bars show SEM.  
 
Second and Third Round of SAR: Modifications to the Phenol and Furan Group  
The first round of SAR analysis revealed the importance of the halogens for Kif15 
inhibition by GW108X.  The next batch of derivatives contained modifications to only the phenol 
ring, leaving the furan tail unchanged. Fourteen compounds were synthesized and tested at 750 
nM in the MT gliding assay (Figure 4.7). Interestingly, compounds that contain two different 
51 
 
halogens (6 and 7) showed intermediary inhibition also in line with respective halogen size. More 
aggressive changes in the aromatic ring substitutions served only to demonstrate the importance 
of the hydroxyl and halogens for robust inhibition of Kif15. For example, removal (10) or 
substitution (19) of the phenolic hydroxyl abolished activity. Furthermore, both halogen 
substituents appear to be required, as compounds with the halogens replaced with methyl groups 
(12) displayed reduced in activity (Figure 4.7). 
The last round of SAR derivatives contained compounds that had modifications to the 5-
position of the oxindole core. We found that the 5-position of the oxindole core was intolerant of 
changes, as these compounds did not robustly inhibit Kif15 MT-gliding (Figure 4.8).  Available 
analogs of GW108X, VU669 and VU724 present in Vanderbilt HTS compound libraries were also 
tested to better understand the structure-activity of Kif15 inhibition. In total, 31 compounds were 
further tested in the ATPase assay (See Appendix Figure A1.1).  
 
Discussion 
This work describes the first published small molecule screen for Kif15 inhibitors. 
Extensive assay development was required not only to discover valid Kif15 inhibitors, but to 
provide future lab members with a reliable and robust assay for future screens. The oxindole 
GW108X was isolated from the GSK PKIS and exhibited a sub micromolar IC50 in both the 
ATPase and MT gliding assays.  Comparable activity between these two different assays suggested 
GW108X may be a true Kif15 inhibitor and encouraged us to pursue GW108X derivatives.  
Although no derivative was superior to GW108X, the SAR campaign highlighted the importance 
of both the halogens and furan tail for Kif15 inhibition. The crystal structure of the motor domain 
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Figure 4.7 SAR analysis of the second round of GW108X derivatives. Compound structures from the 
second round of SAR analysis of GW108X phenol derivatives. Data is the average microtubule gliding velocity 
of Kif15-N700 with each compound at tested 750 nM. Every compound was tested in triplicate with n ≥ 30 
measurements for each replicate, except 10, 14, and 19, which were tested in duplicate. Error bars show 
standard deviation (SD).  
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of Kif15 has been reported and recapitulated in collaboration with the Subramanian lab (Klejnot 
et al. 2014). Despite successful generation of Kif15 crystals, co crystals with GW108X did not 
reveal density corresponding to small molecule binding (unpublished). This is likely due to 
Figure 4.8 SAR analysis of third round of GW108X derivatives. Compound structures from the third 
round of SAR analysis of GW108X derivatives. Data is the average microtubule gliding velocity of Kif15-
N700 with each compound at tested 750 nM. Every compound was tested in triplicate with n ≥ 30 
measurements for each replicate, except 20, which was tested in duplicate. Error bars show standard 
deviation (SD). 
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GW108X insolubility at high concentrations (unpublished).  Regardless, the crystal structure of 
Kif15 will be useful moving forward for any future Kif15 inhibitors discovered in the Ohi lab.  
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A modified version was previously published as:  
Dumas, ME., Chen, GY., Kendrick, ND., Xu, G., Larsen, SA., Jana, S., Waterson, AG., Bauer, 
JA., Hancock, W., Sulikowski, GA., and Ohi, R. (2018) Dual inhibition of Kif15 by oxindole 
and quinazolinedione chemical probes. Bioorg Med Chem Lett. 29(2): 148-154.  
 
 
Introduction 
 GW108X is an oxindole kinase inhibitor first developed by GSK and characterized as a 
potent cRaf-1 inhibitor with an IC50 of 40 nM (Lackey et al. 2000). A decade later, GW108X was 
described as a potent inhibitor of TANK-binding kinase 1 (TBK1), exhibiting an IC50 300 nM 
(Richters et al. 2015).  The most comprehensive study of GSK PKIS, including GW108X, was in 
2016. In this study, the entire PKIS was characterized for its ability to inhibit 224 recombinant 
kinases and 24 G protein-coupled receptors (Elkins et al. 2016). Furthermore, the entire library 
was screened in several cellular assays measuring cell proliferation and angiogenesis.  Not only 
did GW108X inhibit several kinases in-vitro, the authors specifically described GW108X as 
having a “complex and promiscuous GPCR activity profile” (Elkins et al. 2016).  
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 Despite these perceived pitfalls, it is not uncommon for researchers to repurpose kinase 
inhibitors for novel applications. Many examples can be found in the literature using kinase 
inhibitor libraries to discover novel antibiotics and treatments for neglected tropical diseases 
(Dichiara et al. 2017; Miller et al. 2009).  While these examples generally strive to target the 
kinome of other organisms, kinase inhibitors have been used as starting scaffolds to inhibit the 
molecular motor myosin (Islam et al. 2010).  With these successes in mind, we decided to pursue 
GW0108X as a lead compound for development and drug design, characterizing its activity in 
vitro and in vivo.  
 
GW108X is a Reversible Inhibitor 
We used the MT gliding assay to test whether the inhibition of Kif15 by GW108X is 
reversible.  MT gliding by Kif15 was initiated in the presence of DMSO and after roughly a minute, 
10 M of GW108X was added to the flow chamber. Treatment for 1 minute was sufficient to 
eliminate MT gliding.  GW108X was then washed out, replaced with DMSO, and the chamber 
was imaged for another minute. After wash out of GW108X, MTs resumed gliding, revealing that 
GW108X inhibits Kif15 in a reversible manner (Figure 5.1 A). MT gliding was unaffected when 
only DMSO was washed in (Figure 5.1 B).  
 
GW108X has a High Preference for Kif15  
We next tested the ability of GW108X to inhibit Eg5, HSET, and Kif18A, three additional 
mitotic motors that differ in both structure and function (Mountain et al. 1999; Sawin et al. 1992; 
Stumpff et al. 2008).  Despite promiscuity as a kinase inhibitor, GW108X displayed a preference 
for Kif15 over the other mitotic motors tested. For this set of experiments, GW108X was used at 
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a concentration of 30 µM, which completely inhibits Kif15 MT gliding by 98.9%  0.2% while 
only inhibiting Eg5 by 19.8% ± 4.3%, HSET by 5.3% ± 2.9% and Kif18A by .9% ± 3.9 (mean ± 
SEM, Figure 5.1 C). 
 
GW108X is a Non-Competitive ATP Inhibitor  
 In principle, GW108X could inhibit the MT-stimulated ATPase and MT gliding activity of 
Kif15 by inhibiting the motors ability to bind either ATP or MTs.  To distinguish between these 
Figure 5.1 GW108X is a reversible Kif15 inhibitor and has a high preference for Kif15. A) 
Representative montage of fluorescent MTs from the double wash out experiment. Numbers indicate time 
in seconds after initial frame, which are not the same MT for each condition. Scale bar, 5 µm. B) 
Representative montage of fluorescent MTs from control double wash out experiment using DMSO. Each 
vertical frame represents 10 seconds. Scale bar, 5 µm.  C) Percent inhibition of indicated mitotic motors 
treated with 30 µM of GW108X. n >20 for all conditions, **** p < 0.0001, ** p = 0.0074.   
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possibilities, we first measured the MT-stimulated ATPase activity of Kif15-N700 at varying 
concentrations of ATP or MTs in the presence of GW108X. When varying the concentration of a 
substrate, a competitive inhibitor will change the KM while Vmax remains unchanged, whereas a 
non-competitive inhibitor will change the Vmax with no change in the KM. When varying ATP 
concentrations in the presence of GW108X at a high MT concentration, there was no change in 
the measured KM
ATP
 and a decrease in the Vmax, indicating that GW108X is not competing with 
ATP binding (Figure 5.2 A). In contrast, when the MT concentration was varied in the presence 
of saturating ATP, an increase in the KM
MT
 was observed, suggesting that GW108X interferes with 
Kif15’s MT binding ability (Figure 5.2 B).  
 
Figure 5.2 GW108X is a non-competitive ATP inhibitor. (A) Double reciprocal Lineweaver-Burk plot of 
ATP titration at 0.5, 1 and 2 µM GW108X. (B) Double reciprocal Lineweaver-Burk plot of MT titration at 0.5 
and 2 µM GW108X (Geng-Yuan Chen).  
 
GW108X Inhibits Spindle Assembly in K5I Resistant Cells  
 To determine if GW108X affects Kif15 activity in cells, we first analyzed its effects on 
Kif15 localization and activity in TP53-/- RPE-1 cells (Izquierdo et al. 2014).  In RPE-1 cells 
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treated with 25 µM GW108X, 84% of pre-anaphase microtubule arrays were bipolar (n=470), 
similar to cells treated with DMSO (90% bipolar, n=490, Figure 5.3 B).  This is consistent with 
previous reports that Kif15 is not normally required for spindle assembly (Sturgill and Ohi 2013; 
Tanenbaum et al. 2009).  However, 25 M of GW108X led to a 3-fold decrease of spindle-bound 
Kif15 levels compared to DMSO, as assessed by quantitative immunofluorescence microscopy 
(Figures 5 A and C). Decrease in spindle Kif15 levels corresponds to a ~60% decrease in Kif15 
protein levels in RPE-1 cells treated with 25 µM GW108X, suggesting that GW108X treatment of 
cells leads to Kif15 degradation (Figure 5.3 D and E). Despite a decrease of Kif15 in RPE-1 cells 
treated with 25 µM GW108X, spindle lengths were unaffected (Figure 5.3 F).  
 To determine if GW108X inhibits the spindle assembly function of Kif15, we tested 
whether GW108X blocks spindle assembly in an RPE-1 cell line adapted to survive in the presence 
of the kinesin-5 inhibitor STLC. Cancer cell lines can acquire resistance to K5Is, and these K5I-
resistant cell lines (KIRCs) all rely on Kif15 to build a bipolar spindle (Ma et al. 2014; Raaijmakers 
et al. 2012; Saeki et al. 2018; Sturgill et al. 2016; Sturgill and Ohi 2013).  We generated the KIRC-
1 cell line as a clone of TP53-/- RPE-1 cells that adapted to the presence of 10 µM STLC (see 
Materials and Methods). Without further perturbation, KIRC-1 cells exhibit ~50-60% monopolar 
spindles, consistent with previously published K5I-resistant lines listed above (Figure 5.4 B).  
Confirming that Kif15 is essential to complete cell division when Eg5 is inhibited, depletion of 
Kif15 from KIRC-1 cells by RNAi blocked bipolar spindle assembly; 99% of Kif15-depleted 
KIRC-1 cells contained monopolar spindles, compared to 65% in control siRNA-transfected cells 
(Figures 5.4 C and D). To test the effects of GW108X, we scored monopolarity in KIRC-1 cells 
treated with 25 µM of GW108X (in the presence of 10 µM STLC), and found that the compound 
increased the percent of monopolar spindles in KIRC-1 cells from 49 ± 4% to 95 ± 3% (Figure 5.4 
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A and B).  The ability of GW108X to block spindle assembly in KIRC-1 cells was dose-dependent 
(Figure 5.4 D).   
 
Figure 5.3 RPE-1 cells maintain spindle bipolarity when treated with GW108X. A) Max intensity z-
projections of TP53-/- RPE-1 cells treated with DMSO or 25 µM GW108X for 24 hours and stained with 
antibodies targeting Kif15 (grayscale and red), tubulin (green) and DNA (blue). Lookup tables (LUTs) for 
grayscale, red, and green channel are scaled identically. Scale bar, 10 µm. B) Quantitation of % of pre-
anaphase structures in TP53-/- RPE-1 cells treated with DMSO or 25 µM GW108X for 24 hours. Each 
condition was tested in triplicate and n ≥ 100 cells per replicate were counted. Errors bars show SD. C) 
Quantitation of Kif15 on metaphase MTs in TP53-/- RPE-1 cells treated with DMSO or 25 µM GW108X. 
Shown are ratios of Kif15 fluorescence intensities to tubulin intensities. Box-and-whisker plots describe the 
median value as well as the 10th, 25th, 75th and 90th percentiles. ****, p < 0.0001. n ≥ 25 cells from triplicate 
experiments. D) Western blot of whole cell lysates prepared from RPE-1 cells treated with DMSO or 25 µM 
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GW108X for 24 hours and probed with antibodies targeting Kif15 (α-Kif15) and tubulin (DM1α). E) 
Quantitation of A. Values represent levels of Kif15 protein in GW108X treated cells normalized to DMSO 
treatment. n = 2, error bars, SD.  F) Quantitation of spindle lengths in TP53-/- RPE-1 cells treated with DMSO 
or 25 µM of GW108X for 24 hours. Box-and-whisker plots describe the median value as well as the 10th, 
25th, 75th and 90th percentiles.  
 
Figure 5.4 GW108X prevents spindle assembly in KIRC-1 cells. A) Max intensity z-projections of KIRC-
1 cells treated with DMSO or 25 µM GW108X for 24 hours and stained with antibodies targeting Kif15 
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(grayscale and red), tubulin (green) and DNA (blue). Lookup tables (LUTs) for grayscale, red, and green 
channel are scaled identically. Scale bar, 10 µm. B) Quantitation of % of pre-anaphase structures in KIRC-
1 cells treated with DMSO or 25 µM GW108X for 24 hours. Each condition was tested in triplicate and n ≥ 
100 cells per replicate were counted. Errors bars show SD. C) Quantitation of pre-anaphase structures in 
KIRC-1 cells transfected with control or Kif15 siRNA. Each condition was repeated in triplicate and graph 
displays average percent from each triplicate. Error bars show SD. D) Western blot of whole cell lysates 
prepared from KIRC-1 cells transfected with control or Kif15 siRNA and probed with antibodies targeting 
Kif15 (α-Kif15) and tubulin (DM1α). E) Quantitation of monopolar spindles in KIRC-1 cells treated with 
varying concentrations of GW108X or DMSO. Each condition was repeated in triplicate and graph displays 
average percent from each triplicate. Error bars show SEM. 
 
Figure 5.5 Monopolar spindles dominant 2 hours after GW108X removal. Preliminary quantitation of 
KIRC-1 pre-anaphase spindle structures after GW108X removal. KIRC-1 cells were treated with 25 µM 
GW108X for 24 hours before GW108X removal. Time indicates time after GW108X removal. N ≥ 94 for all 
conditions from one experimental replicate.  
 
Discussion  
 Although GW108X is a kinase inhibitor, our data demonstrates that this small molecule 
can successfully inhibit Kif15 in-vitro and produces phenotypes similar to Kif15 knock-down. 
GW108X is reversible in the MT gliding assay, though it remains unknown if this translates into 
cells. If GW108X is indeed reversible in cells, it would be an exciting tool compound to temporally 
regulate Kif15 activity. In KIRC-1 cells, Kif15 is required for spindle bipolarity (Figure 5.4), but 
we cannot exclude the possibility that the increase of monopolar spindles in the presence of 
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GW108X is not due to mechanisms beyond Kif15 inhibition. Since GW108X is a broad-spectrum 
kinase inhibitor, it is possible that a block in spindle assembly is partly due to co-inhibition of a 
mitotic kinase(s).  Importantly, such kinase inhibitor activity is tolerated in RPE-1 cells, as spindle 
assembly is not prevented in the parental cell line. In HeLa K5I-resistant cell lines, monopolar 
spindles can arise from the combined inhibition of Eg5 and Aurora A Kinase (AURKA, Ma et al. 
2014).  Furthermore, phosphorylation of Kif15 by AURKA is required to target Kif15 to the 
spindle (van Heesbeen et al. 2017).  While biochemical analysis revealed that GW108X inhibits 
AURKA 67% at 1 µM, it is unknown if GW108X effectively inhibits AURKA in cells (Elkins et 
al. 2016).   
 In cell-based assays, GW108X had no adverse effects on parental RPE-1 cells but 
significantly increased the percent of monopolar spindles in the K5I resistance KIRC-1 cell line 
(Figure 5.3). When RPE-1 cells were treated with 25µM of GW108X, the spindle bound Kif15 
intensity in RPE-1 cells decreases 3x fold.  Despite this, they are able to achieve bipolarity most 
likely through the activity of Eg5 (Sturgill and Ohi 2013; Tanenbaum et al. 2009). In agreement 
with this data, Kif15 protein levels are decreased ~60% in RPE-1 cells treated with GW108X. It 
is unclear why GW108X is causing Kif15 degradation. Perhaps GW108X treatment causes Kif15 
destruction directly by inducing Kif15 aggregation. This could be confirmed by examining the 
ubiquitination of Kif15 in cells treated with GW108X.  
 It will be important moving forward to determine if GW108X and subsequent derivatives 
reach Kif15 in cells. An interesting and relatively simple experiment would be to use a Kif15-GFP 
cell line and use live cell microscopy to measure Kif15 loss from the spindle upon addition of 
GW108X. Preliminary data suggests that the acute effects of GW108X in KIRC-1 cells lasts for 
at least 2 hours, but further work is needed to estimate cell retention time (Figure 5.5).  
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Furthermore, it is critical for any potential Kif15 inhibitor to be tested in combination with K5Is 
to confirm that dual pharmacological inhibition of both kinesins eliminates resistant colony 
formation in tissue culture cells (Appendix A.2).  
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Introduction 
 In 2004, the company Cytokinetics submitted a patent application titled “Preparation of 
quinazolinediones as Kif15 kinesin inhibitors for treating cellular proliferative disorders” 
(McDonald et al. 2004). A patent application does not require the submission of experimental data, 
and since a patent was never issued, the effectiveness of these compounds remains unknown. 
Regardless, over 10 years later, a compound from that patent application became commercially 
available and called Kif15-IN-1. The first academic lab to publish experimental data with Kif15-
IN-1 was the Block group at Stanford University (Milic et al. 2018).  Although the paper largely 
reports on the mechanochemical cycle Kif15, Milic et al demonstrated that Kif15-IN-1 works 
synergistically with K5Is to decrease cell viability in HeLa cells.  While their experiments were 
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thorough, the group did not investigate the effect Kif15-IN-1 had on Kif15 inside cells. To fill this 
gap, we purchased Kif15-IN-1 to use in several of our established Kif15 assays.  
 
Kif15-IN-1 Displays a Sub-Micromolar IC50  
 Kif15-IN-1 is a quinazolinedione and is reported to have an IC50 of 1.72 µM in the MT 
gliding assay (Figure 6.1 A). We repeated the MT gliding assays using the reported IC50 of 1.72 
µM and found that this concentration abolishes Kif15-driven MT gliding (Figure 6.1 B). We used 
the MT gliding assay to calculate our own IC50, revealing an IC50 of 203 nM (Figure 6.1 C).  This 
concentration is lower than the previous reported, and possibilities for this discrepancy are 
highlighted in the discussion.  
 
Figure 6.1 Sub-micromolar IC50 of Kif15-IN-1 in MT gliding assay. A)  Structure of Kif15-IN-1. B) 
Representative still frames from MT gliding assay with or without 1.72 M Kif15-IN-1. MTs from the first 
and last frame of movie are pseudo-colored in red and green, respectively. Scale bar, 20 m. C) 
Concentration response curve using the MT-gliding assay, developed from 5 concentrations of Kif15-IN-1, 
ranging from 30 to 0.1 M (George Xu). Error bars show SD.   
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Kif15-IN-1 is Reversible and Competes with ATP 
 The study published from the Block lab focused on understanding the mechanochemical 
cycle of Kif15 using single molecule optical trap assays to compare Kif15 to Eg5.  They also used 
mixed motor MT gliding assays with recombinant Eg5 and Kif15 to understand how K5Is and 
Kif15-IN-1 may affect teams of mitotic motors within the spindle.  Despite having all of these 
reagents, they did not report if Kif15-IN-1 was reversible. For this, we again turned to the MT 
gliding assay to determine if MTs will resume gliding when Kif15-IN-1 is washed out. Similar to 
GW108X, Kif15-IN-1 was reversible in the MT gliding assay (Figure 6.2 A).  
 We next used the steady state ATPase assay to determine if Kif15-IN-1 was ATP-
competitive. In contrast to GW108X, an increase in KM
ATP was observed when the ATP 
concentration was varied in the presence of Kif15-IN-1, indicating that instead of competing with 
MT binding, Kif15-IN-1 competes with ATP binding (Figure 6.2 B).  
Figure 6.2 Kif15-IN-1 is a reversible, ATP competitive inhibitor of Kif15. A) Representative montage of 
fluorescent MTs from double wash out experiment. Each vertical frame represents 10 seconds. Scale bar, 
5 m. B) Double reciprocal Lineweaver-Burk plot of ATP titration using 5 M Kif15-IN-1. Each reaction was 
performed in triplicate (Geng-Yuan Chen). Error bars shows SEM.  
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Kif15-IN-1 Decreases Mitotic Spindle Length 
 The only cellular data of Kif15-IN-1 is from cell viability assays (Milic et al. 2018).  Milic 
et al demonstrated that K5Is and Kif15-IN-1 work synergistically to decrease HeLa cell viability, 
but did not characterize Kif15 localization inside cells treated with Kif15-IN-1. To start, we tested 
the effect of Kif15-IN-1 on Kif15 localization in RPE-1 cells. Similar to GW108X, RPE-1 cells 
treated with Kif15-IN-1 maintained bipolarity (Figure 6.3 A-B, DMSO: 94% bipole, n = 303, 
Kif15-IN-1: 96% bipole, n = 196).  Unlike GW108X, Kif15-IN-1 did not reduce spindle-bound 
levels of Kif15 and only decreased Kif15 protein in whole cell lysates by 15% (Figure 6.3 C and 
E-F). Nevertheless, spindles were shorter in RPE-1 cells treated with 25 µM Kif15-IN-1 (9.9 µm 
± 0.3 µm) compared to DMSO (11.4 µm ± 0.2 µm), a phenotype consistent with knock-down of 
Kif15 (Figure 6.3 D, Sturgill & Ohi, 2013). 
 
Kif15-IN-1 Prevents Spindle Assembly in KIRC-1 Cells  
 Finally, we tested whether Kif15-IN-1 had the ability to halt spindle assembly in the KIRC-
1 cell line that relies on Kif15 for bipolarity (Figure 5.4 D). In KIRC-1 cells treated with 25 µM 
Kif15-IN-1, the percentage of pre-anaphase microtubule arrays that were monopolar increased 
from 43% in DMSO (n = 260) to 84% (Figure 6.4 A and B, n = 269), similar to the increase 
observed with GW108X. 
 
Discussion 
 The quinazolinedione Kif15-IN-1 has only been studied previously by one academic group 
and was found to inhibit Kif15 in vitro (Milic et al. 2018).  Until now, it was unknown how Kif15-
IN-1 may be altering Kif15 in cells.  Here in, we characterized Kif15-IN-1 in both RPE-1 and 
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KIRC-1 cells, and compared it to GW108X. In the MT gliding assay, we estimated an IC50 of 203 
nM for Kif15-IN-1. However, Kif15-IN-1 has previously been reported to have an IC50 of 1.72  
 
 
Figure 6.3 Kif15-IN-1 has no effect on Kif15 localization or protein levels in RPE-1 cells. A) 
Representative single optical sections of TP53-/- RPE-1 cells treated with DMSO or 25 µM Kif15-IN-1 for 24 
hours and stained for antibodies targeting Kif15 (grayscale and red), tubulin (green) and DNA (blue). LUTs 
for grayscale, red and green channels are scaled identically. Scale bar, 5 µm. B) Quantitation of the % pre-
anaphase structures in TP53-/- RPE-1 cells treated with DMSO or 25 µM Kif15-IN-1 for 24 hours. Each 
condition was tested in triplicate and graph displays average percent from each triplicate. Errors bars show 
SD. C) Quantitation of RPE-1 cells treated with DMSO or 25 µM Kif15-IN-1 for 24 hours. Shown are ratios 
of Kif15 fluorescence intensities to tubulin intensities. Box-and-whisker plots describe the median value as 
well as the 10th, 25th, 75th and 90th percentiles. n = 30 cells from triplicate experiments. D) Quantitation of 
spindle lengths in TP53-/- RPE-1 cells treated with DMSO or 25 µM of Kif15-IN-1 for 24 hours. Box-and-
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whisker plots describe the median value as well as the 10th, 25th, 75th and 90th percentiles. E) Western blot 
of whole cell lysates prepared from TP53-/- RPE-1 cells treated with DMSO or 25 µM Kif15-IN-1 for 24 hours 
and probed with antibodies targeting Kif15 (α-Kif15) and tubulin (DM1α).  F) Quantitation of E. Values 
represent levels of Kif15 protein in Kif15-IN-1 treated cells normalized to DMSO treatment. n = 2, error bars 
show SD. 
 
 
Figure 6.4 Kif15-IN-1 prevents spindle assembly in KIRC-1 cells. A) Quantitation of the % pre-anaphase 
structures in KIRC-1 cells treated with DMSO or 25 µM Kif15-IN-1 for 24 hours. Each condition was tested 
in triplicate and graph displays average percent from each triplicate. Errors bars show SD. B) 
Representative max intensity projection of KIRC-1 cells treated with DMSO or 25 µM Kif15-IN-1 for 24 hours 
and stained for antibodies targeting Kif15 (grayscale and red), tubulin (green) and DNA (blue). LUTs for 
grayscale (Kif15) are scaled identically. Scale bar, 10 µm. 
 
µM in the same assay.  While reasons for this discrepancy remain unclear, the most notable 
difference between assay conditions is the use of different Kif15-N700 constructs.  We have 
previously characterized a Kif15-N700 construct generated from a naturally occurring mRNA 
variant of Kif15 that lacks the AA residues 8-21 (Sturgill et al. 2014). The Kif15 construct from 
the Milic study contained these AAs and exhibits ~1.5x increase in MT gliding velocity compared 
to our construct. Regardless, it is unlikely that these AAs are required for Kif15-IN-1 binding, as 
a lack of crucial AA’s would only increase the predicted IC50, not lower it. 
 In the mixed motor gliding assays with Eg5 and Kif15, Milic et al reported that when Kif15 
was fully inhibited by Kif15-IN-1, Eg5 was unable to reach its characterized gliding velocity. This 
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observation suggests that Kif15 complexed with Kif15-IN-1 strengthens Kif15 binding to MTs, 
and acts as a ‘brake’ to Eg5 powered motility. Despite the observation that Kif15-IN-1 may rigor 
Kif15 to the MT lattice, we did not observe a change in Kif15 levels on the spindle (Figure 6.3 C). 
Furthermore, we did not observe an increase in the % of Kif15 in the pellet of a MT co pellet assay 
in the presence of Kif15-IN-1 (data not shown). Regardless of rigor ability, treatment of RPE-1 
cells with Kif15-IN-1 displayed the characteristic short spindle phenotype of Kif15 inhibition and 
prevents spindle assembly in KIRC-1 cells.  
 Moving forward, several important experiments are necessary to fully understand the 
specificity of Kif15-IN-1 for Kif15 inside cells. First, a kinase inhibition profile to probe potential 
off target effects would determine if Kif15-IN-1 has any promiscuous kinase inhibition behavior. 
Furthermore, it would be useful to understand Kif15-IN-1’s preference for Kif15 over other mitotic 
motors. Block et al demonstrated Kif15-IN-1 has no effect on Eg5 activity, but other kinesins 
should be tested.  
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CHAPTER 7 
 
CONCLUDING REMARKS 
 
Targeting Kif15 Intramolecular Interactions     
 Kinesins are the molecular work horses of the cell, uniquely able to harness and translate 
the energy from ATP hydrolysis into force generation.  During interphase, kinesins are one of the 
main transport motors, using the MT highway to transport vesicles, signaling granules, and 
organelles (Alberts et al. 2008).  During cell division, mitotic kinesins drive centrosome separation, 
chromosome congression, and cytokinesis (Cross and McAinsh 2014).  Owing to their importance, 
deregulation of mitotic kinesins has been associated with the development of a variety of cancers, 
and are therefore attractive chemotherapeutic targets (Kozielski 2012; Qiao et al. 2018; Yu et al. 
2019). 
Regulating kinesin activity is paramount to prevent both kinesin hyper activity and waste 
of ATP. As described in the introduction, cells have a toolbox of techniques to prevent 
uncontrolled kinesin activity, including self-regulation, post translational modifications, and 
sequestration (Verhey and Hammond 2009).  Kif15 is an autoinhibited motor that is regulated in 
a cell cycle dependent manner, whose preference for MT bundles promotes its localization to K-
MTs during mitosis (Sturgill et al. 2014).  Kif15 over expression promotes tumorgenicity and is 
correlated with poor prognosis in melanoma, breast, bladder, and lung cancers (Qiao et al. 2018; 
Song et al. 2018; Yu et al. 2019; Zhao et al. 2019).  In tissue culture, Kif15 overexpression is one 
mechanism used by cells to acquire K5I resistance (Sturgill and Ohi 2013).  Though not confirmed, 
one would predict that a subset of cancer samples from patients treated with a K5I during a clinical 
trial would also exhibit elevated Kif15 levels.  Another mechanism to confer K5I resistance could 
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involve mutations that abrogate the ability of Kif15 to auto-inhibit its activity. A mutation of this 
nature in the gene encoding KIF21A, a kinesin that suppresses MT growth in neurons, gives rise 
to the congenital neurodevelopmental disorder congenital fibrosis of the extraocular muscles type 
1 (Cheng et al. 2014; van der Vaart et al. 2013).  Over all, knowledge of how Kif15 self regulates 
will shed light on how the motor regulates its activity in both space and time, and has the potential 
to explain a novel pathway cancer cells may use to evade the lethal effects of kinesin-5 inhibitors. 
 A deep understanding of the intramolecular interactions between Kif15 and its inhibitory 
tail may also guide the design of small molecule mimetics that exploit this region.  Kif15 auto-
inhibition depends on the LZ motif as well as other sequences within the last 100 AAs of the C-
terminal tail (Figure 3.1 C). Knowledge of the residues key for inhibition will be critical in 
understanding the biochemical and structural mechanism of Kif15 auto-inhibition. Nature has 
already designed a Kif15 inhibitor that can be extrapolated to design small molecules that target 
the auto-inhibitory region within the motor domain (Peterson and Golemis 2004).  Small molecule 
inhibitors have been designed that stabilize the inhibited conformation of self-regulated proteins 
as well as block antagonist activator binding interactions (Wang 2010; Wu et al. 2018).  Even more 
promising, proof of principle studies with kinesin-1 demonstrated that small molecules can be used 
to manipulate the auto-inhibition state of the kinesin (Randall et al. 2017).  A deep knowledge of 
the interaction between Kif15’s tail and MD, combined with the crystal structure of Kif15, could 
propel Kif15 inhibitor development.  
 
Targeting Kif15 Pharmacologically  
 The bipolar geometry of the mitotic spindle is both iconic and essential. Its fusiform shape 
is the only geometry that can successfully complete the mission of mitosis. In order to create 
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bipolarity, the spindle MTs must be focused within centrosomes at either end of the structure (Yang 
and Snyder 1992).  The majority model organisms studied in the lab require Eg5 to separate the 
duplicated centrosomes, with the exception being C. elegans and Dictyostelium (Bishop et al. 
2005; Tikhonenko et al. 2008). This seemingly universal requirement for Eg5 in spindle assembly 
skyrocketed its appeal as a chemotherapeutic target, with several pharmaceutical companies 
pouring money into K5I discovery campaigns and clinical trials (Kozielski 2012). To date, all 
clinical trials with K5Is have failed and several research groups have reported K5I resistance 
mechanisms that depend on Kif15 in tissue culture cells (Ma et al. 2014; Raaijmakers et al. 2012; 
Sturgill et al. 2016; Sturgill and Ohi 2013).  
 Using small molecule screening techniques to discover a novel function for GW108X and 
purchasing Kif15-IN-1, we have described and characterized two functionally unique Kif15 
inhibitors. Despite being a known kinase inhibitor, GW108X is a potent and reversible inhibitor 
of Kif15 in vitro. The quinazolinedione, Kif15-IN-1, was discovered in 2004 by Cytokinetics and 
recently became available for scientific use. Both compounds are sub-micromolar inhibitors of 
Kif15 and exhibit different mechanisms of inhibition. Steady state kinetics confirmed that while 
Kif15-IN-1 directly competes with ATP, GW108X instead is a non-ATP competitive inhibitor and 
interferes with Kif15s MT binding ability. Further work is required to determine if GW108X is 
trapping Kif15 in a low MT affinity state by preventing ADP release or direct obstruction of 
Kif15’s MT binding site. Since GW108X and Kif15-IN-1 display different modes of inhibition, it 
is unlikely that they share the same binding site within the motor and instead each offer novel 
chemical space for Kif15 inhibition.  
 This distinction in biochemical mechanism is important for two reasons. First, having 
multiple sites to probe for inhibition increases the likelihood of creating a truly Kif15 specific 
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inhibitor.  If the binding site for GW108X and Kif15-IN-1 are close, it could be feasible to create 
a large, flexible molecule that encompasses properties of both compounds, allowing for both 
inhibitory regions to be engaged.  Conjugation of two chemotypes might improve specificity and 
affinity of the inhibitor.  Secondly, having two druggable sites decreases the possibility of 
mutations within KIF15 bypassing drug mechanism, a common challenge of target-based 
chemotherapeutics (Schmitt et al. 2016).  Improving the specificity and potency of both GW108X 
and Kif15-IN-1 relies on obtaining co-crystals of these small molecules with the Kif15 motor 
domain (Klejnot et al. 2014).  
 Mitotic kinesin inhibitors are routinely used in cell biology laboratories and allow 
researchers to specifically modulate a motors activity to give a predicted perturbation of MT or 
spindle dynamics. For example, research in Xenopus extracts using a rigor K5I (instead of the 
previously characterized allosteric K5Is) specifically induced loss of microtubule density at the 
spindle poles, unmasking a novel role for Eg5 activity in spindle pole maintenance (Groen et al. 
2008). Recently, functionally distinct K5Is were shown to have differential effects on both MT 
dynamics in vitro and spindle stability in RPE-1 cells.  While the canonical non-competitive loop-
5 targeting K5Is result in the classic monopolar spindle phenotype, the ATP competitive inhibitor 
BRD9876 stabilizes MTs in vitro and does not cause spindle collapse (Chen et al. 2017).  
 Small molecule inhibitors that can modulate Kif15’s mechanochemical cycle in different 
ways will also be powerful tools for mitosis research. In the case of Kif15, its mitotic function 
under normal conditions is not well understood.  Kif15 localizes to kinetochore-MTs, regulating 
the stability and length of these bundles.  When over-expressed, as in some K5I-resistant cells, 
Kif15 re-localizes to non-KMTs and provides outward forces required for centrosome separation 
(Sturgill and Ohi 2013). Small molecules that can acutely inhibit Kif15 in these different cellular 
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contexts through different mechanisms are likely to reveal new properties and functions of Kif15 
during mitosis. 
 Our studies with GW108X and Kif15-IN-1 show that both compounds are useful launch 
points in the generation of Kif15-targeting drugs. Given that cultured cells must express KIF15 in 
order to acquire K5I resistance and that K5Is synergize with Kif15-IN-1 to decrease in cell 
viability, there is clear rationale to pursue Kif15-targeting drugs for use in combination with K5Is 
as a chemotherapeutic strategy (Milic et al. 2018; Sturgill et al. 2016).  
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APPENDIX 
 
A.1 STRUCTURE-ACTIVITY RELATIONSHIP ANALYSIS OF GW108X, VU669, AND 
VU724 STRUCTURAL ANALOGS 
 
 
 Screening of the GSK PKIS led to three potential lead compounds: GW108X, VU669 and 
VU724 (see Figure 4.3). The Vanderbilt High Throughput Screening facility has several 
commercial and private compound libraries available for researchers. Before synthesizing a 
GW108X derivative library, we wanted to take advantage of the large resource of compounds 
available for use to probe the SAR of the top three compounds. With the help of medicinal 
chemists, 31 compounds were selected from 11 different compound libraries and screened in 
triplicate at 10 M for their ability to inhibit Kif15-N420 in the ATPase assay screen (Figure A1.1 
– 1.3). 
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Figure A1.1 SAR analysis of GW108X structural analogs. Compounds cherry-picked from available 
Vanderbilt small molecule libraries that shared structural features with GW108X. Data is the average 
percent inhibition of Kif15-N420 with each compound using the ADP-Glo ATPase assay. Every compound 
was tested in triplicate.  
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Figure A1.2 SAR analysis of VU669 structural analogs. Compounds cherry-picked from available 
Vanderbilt small molecule libraries that shared structural features with VU669. Data is the average percent 
inhibition of Kif15-N420 with each compound using the ADP-Glo ATPase assay. Every compound was 
tested in triplicate. 
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Figure A1.3 SAR analysis of VU724 structural analogs. Compounds cherry-picked from available 
Vanderbilt small molecule libraries that shared structural features with VU724. Data is the average percent 
inhibition of Kif15-N420 with each compound using the ADP-Glo ATPase assay. Every compound was 
tested in triplicate. 
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A.2 CAN GW108X OR ITS DERIVATIVES PREVENT K5I RESISTANCE IN RPE-1 
CELLS? 
 
 Previous work from our lab demonstrated that pharmacological inhibition of Eg5 and 
genetic deletion Kif15 abolished the ability of HeLa cells to develop resistance against K5Is 
(Sturgill et al. 2016).  This proof of principal discovery demonstrated that regardless of resistance 
mechanism, tissue culture cells required Kif15 to develop K5I resistance, underscoring the 
importance of developing Kif15 inhibitors. HeLa cells are highly aneuploid, therefore we wanted 
use a non-cancerous cell line to confirm that Kif15 is required for K5I resistance. We generated 
RPE-1 KIF15Δ cells from the diploid RPE-1TP53 -/- cell line and demonstrated that K51 resistant 
colonies were unable to form when KIF15 was deleted (Izquierdo et al. 2014, data not shown).  
 While genetic deletion of Kif15 highlighted its essential role in K5I resistance in these 
cells, the end goal is to eliminate K5I resistance with a small molecule.  With this in mind, RPE-
1TP53 +/+ and RPE-1TP53-/- cells were plated at confluency, treated with 10 µM STLC and 20 µM 
GW108X for 30 days and stained with crystal violet (Figure A2.1).  Between the two cell lines, 
there were clear and unexpected differences between each experimental treatment. As expected, 
based off RPE-1 KIRC generation (see Chapter 5 and Materials and Methods), cells that had active 
p53 did not induce apoptosis when treated with STLC. Cell density decreased during the 30-day 
STLC treatment, but many viable cells remained by the end of the experiment. Though not 
confirmed, this is presumably through p53 mediated senescence (Bieging et al 2014).  In contrast, 
RPE-1 p53-/- had massive cell death and the appearance of resistant colony formation, presumably 
unable to initiate senescence like their RPE-1 p53+/+ counterpart. The cellular response between 
the cell lines is reversed in GW108X treatment, with RPE-1 p53+/+ experiencing massive cell 
death, unlike RPE-1 p53-/-. Finally, both cell lines contain viable cells after 30-day treatment with 
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both STLC and GW108X, with dual treatment appearing to be more effective in RPE-1 p53+/+ 
cells.   
 
  
 
One hypothesis for these results is that STLC and GW108X illicit different cellular 
responses that depend on the p53 status of the cell. When p53 is present, STLC may cause the 
majority of cells to senesce. Since Eg5 is a mitotic motor, STLC can only induce negative effects 
if a cell enters the cell cycle, thus senescence would be a logical way to bypass a catastrophic 
monopolar mitosis.  When p53 is absent and cells are treated with STLC, senescence is not induced 
and the majority of the cells continue through the cell cycle with STLC present. A simple way to 
test this hypothesis would be to treat RPE-1 p53+/+ and p53-/- with STLC and probe for senescence-
associated beta-galactosidase (SA-βgal, Debacq-Chainiaux et al. 2009).  
Figure A2.1 Combined STLC and GW108X Treatment. Representative images of 10 cm dishes 
seeded with indicated cell type and treated with STLC alone, GW108X alone, or both for 30 days 
and stained with crystal violet. Scale bar 5 cm.  
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 The result with GW108X is even more perplexing and likely due its ability to inhibit 
several kinases in-vitro (Elkins et al. 2016). By comparing GW10X treatment alone between the 
two cell lines, it seems reasonable to conclude that GW108X activates a p53 dependent apoptosis 
pathway. If true, one would predict that GW108X is ineffective in killing cancer tissue culture cell 
lines, since lack of p53 activity is a hallmark of several cancers (Alberts et al. 2008).  When tested 
against 60 different cancer cell lines, GW108X displayed LC50 below 25 µM, revealing that cancer 
cell lines are indeed sensitive to GW108X treatment (Elkins et al. 2016).  Regardless, these results 
demonstrate that long-term treatment with both STLC and GW108X in RPE-1 p53-/- cells produces 
an intermediate cellular response that is in-between what is observed with STLC or GW108X 
alone.  
 Preliminary experiments performed by Dr. Sturgill support the hypothesis that cells are 
forced into an evolutionary bottleneck when treated with K5Is (unpublished, Sturgill et al. 2016).  
Cells that survive K5I treatment can develop resistance to K5Is using different mechanisms, such 
as over expression of Kif15 or mutations in Eg5, but we hypothesize they require Kif15 to survive 
the initial bottleneck (Sturgill et al. 2016; Sturgill and Ohi 2013). Furthermore, it is possible that 
GW108X has off target effects or a complex relationship with STLC that manifests in resistant 
colony formation unrelated to Kif15. With these thoughts in mind, we redesigned the previous 
experiment to include variations in length of Kif15 inhibition. For this set of experiments, we 
hoped to conserve the GW108X stock and instead used compound 2, which behaved similarly to 
GW108X in the MT gliding assay (Figure 4.6).  RPE-1 p53-/- cells were treated continuously with 
10 µM STLC for 30 days but with 20 µM of compound 2 for 3, 7, 10, or 14 of those days (Figure 
A2.2).  After 2 removal, cells remained cultured with STLC until day 30.  
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 Interestingly, the longer the treatment of compound 2, the less sensitive cells were to Eg5 
inhibition by STLC.  Cells treated with compound 2 for 3 days visually had fewer viable cells after 
the 30-day experiment.  While it is clear that STLC and GW108X or 2 have a complex relationship 
in cells, this preliminary data hints there may be a critical time point for Kif15 inhibition before 
off target effects dominant with these oxindole derivatives.  Of course, the obvious caveat is the 
lack of knowledge regarding the in vivo targets for GW108X and its derivatives.  Future directions 
include shortening the incubation with GW108X below three days to observe if resistant colony 
formation if further decreased.  
 
 
Figure A2.2. Resistant colony formation with STLC and varying incubations with compound 2. Top) 
Structure of 2 and representative images of 10 cm dishes of RPE-1 p53-/- cells treated with DMSO or STLC 
continuously for 30 days. Bottom) Representative images of 10 cm dishes treated with STLC for 30 days  
and 2 for the number of days listed about each dish. Scale bar 5 cm.  
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